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ABSTRACT 
Assessment of cardiac function is a fundamental in everyday clinical decision 
making and is essential diagnostic tool for choosing therapy in patients with 
cardiac disease. Currently, echocardiography is the integral part in 
management of patients with different cardiac disease and the most 
established imaging tool in the assessment of cardiac function. Coronary 
artery bypass grafting (CABG) is an effective treatment in selected patients 
suffering from advanced coronary artery disease (CAD). Improvement in 
symptoms, functional status and cardiac function is often used to evaluate 
the success of CABG. Evaluation of cardiac function often is divided in 
assessment of systolic and diastolic function. However, systole and diastole 
are integrated and interconnected parts of cardiac cycle. Thus, a method for 
quantifying cardiac function which incorporates both systole and diastole is 
to be preferred. Myocardial performance index (MPI) assessed by pulsed-wave 
Doppler tissue imaging (PW-DTI) is combining systole and diastole, easy to 
acquire and is independent of cardiac geometry. The aim of this thesis is to 
evaluate the feasibility of MPI measured by PW-DTI in assessment of left and 
right ventricular performance  in patients with CAD treated with CABG. In 
addition, to explore the role of B-type natriuretic peptide (BNP) in predicting 
long-term major adverse outcomes following CABG and exploring its 
association with MPI. Finally, this thesis aims to evaluate the impact of 
conventional aortic valve surgery in comparison to minimally invasive aortic 
valve surgery (MIAVR) on right ventricular function (RV) assessed by 
echocardiography. 
 
Methods and Results 
 
Study I, forty six patients who were accepted for CABG were included. They 
all were investigated by dobutamine stress-echocardiography (DSE) prior to 
CABG and  3 month after CABG. Several methods for evaluation of left 
ventricular systolic and diastolic function had been applied, i.e. EF, 
longitudinal systolic and diastolic velocities as well as MPI. All the 
measurements were performed at rest and at peak DSE. The values from pre-
CABG were compared to those after CABG. At baseline, MPI was prolonged 
both at rest (0.61 ±0.13) and at peak DSE (0.78±0.16). Accordingly, ejection 
fraction (EF) was also impaired at rest (42.7±8%) and at peak DSE (49.2±9). 
Similarly, wall-motion score index WMSI was impaired at rest (1.1±0.2) and 
at peak DSE (1.4±0.2). After CABG, MPI improved significantly both at rest 
(0.45±0.08; P < 0.001) and at peak DSE (0.56±0.1; P < 0.001). On the other 
hand, EF and WMSI did not improve at rest (43.7±8% and 1.1±0.2, 
respectively). However, at peak DSE an improvement of both EF (54.2±9; P < 
0.05) and WMSI (1.1±0.16; P < 0.001) was observed.  
 
Study II The same patient cohort as in study I was used for analyzing the 
impact of CABG on RV function. Coronary angiography, DSE and exercise 
bicycle test were performed 1 month before and 3 months after CABG. Right 
ventricular index of myocardial performance (RIMP), right ventricular systolic 
velocity (RVS) and displacement (TAPSE) at the lateral tricuspid annulus were 
all assessed. The RIMP improved following CABG both at rest (0.45 ± 0.11 vs. 
0.38 ± 0.08 CABG, P = 0.013) and during DSE (0.75 ± 0.23 vs. 0.49 ± 0.14, P 
< 0.001). Compared to baseline, TAPSE reduced substantially after CABG 
both at rest (23.9 ± 4.46 vs. 14.6 ± 3.67, P < 0.001) and during DSE (20.9 ± 
4.16 vs 11.9 ± 3.60, P < 0.001). A significant decline in RVS was also observed 
following CABG both at rest (11.9 ± 2.40 vs. 8.5 ± 1.93, P < 0.001) and during 
DSE (15.6 ± 4.30 vs. 10.5 ± 3.21, P < 0.001). On contrary, compared to pre-
CABG values exercise capacity improved significantly following CABG (128.4 
± 40.12W vs 142.1 ± 46.73 W, P = 0.014). 
 
Study III was a predefined post hoc analysis of CMILE study (Cardiac 
Function after Minimally Invasive Aortic Valve Implantation including 40 
patients with severe aortic stenosis and eligible for isolated aortic valve 
replacement. The patients were randomized 1:1 either to conventional aortic 
valve replacement (AVR) or minimally invasive aortic valve replacement 
(MIAVR). The impact of these two surgical techniques on right ventricular 
mechanics and contractility was evaluated by echocardiography. Compared 
to baseline RV strain rate (RV-LSR) was preserved after MIAVR (-1.52±0.5 vs 
-1.49±0.4 1/s, p=0.84) but declined following AVR (-1.67±0.3 vs -1.38±0.3 
1/s, p<0.01). RV longitudinal strain (RV-LS) was deteriorated after AVR 
(˗27.4±2.9% vs ˗18.8±4.7%, p<0.001) and MIAVR (˗26.5±5.3% vs ˗20.7±4.5%, 
p<0.01). Peak systolic velocity of the lateral tricuspid annulus (RVS) declined 
by 18.8% in the MIAVR group (10.1±2.9 vs 8.2±1.4 cm/s, p<0.01) and 36.6% 
in the AVR group (9.3±2.1 vs 5.9±1.5 cm/s, p<0.01) when values from before 
surgery were compared to after surgery. 
 
In Study IV, 99 patients with CAD who underwent CABG were evaluated by 
a biomarker BNP and Echocardiography. In a subpopulation of 40 patients 
  
DTI and MPI were obtained. Patients were followed-up for 5 years and during 
this period death, myocardial infarction, stroke and hospitalization due to 
heart failure were recorded. The role of postoperative BNP for predicting major 
outcomes was assessed and its association with MPI was determined. 
Seventeen  patients experienced major adverse outcomes during the follow-
up. Univariate analysis revealed that creatinine clearance (P<0.01), body 
mass index (BMI, P<0.01), postoperative BNP (P<0.001) and preoperative LV-
MPI (P=0.04) were all significantly associated with major outcomes at follow-
up. However, after correcting for cofactors in multivariate analysis only 
postoperative BNP (P=0.003) and BMI (P=0.025) were associated with major 
outcomes. 
 
CONCLUSIONS: Myocardial performance index and right ventricular index of 
myocardial performance improved significantly following CABG in patients 
with CAD both at rest and peak DSE and appear to be a sensitive measure of 
myocardial function in patients with CAD. Postoperative BNP obtained in a 
stable clinical condition, 3 month after CABG is a predictive of major 
outcomes 5 years after CABG. Load-independent contractility is preserved 
following MIAVR but reduced following AVR. Load-dependent measures of 
myocardial function all declined following both MIAVR and AVR however, to 
a much lesser extent following MIAVR. 
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1 INTRODUCTION 
1.1 EVOLUTION OF ECHOCARDIOGRAPHY, 
USING SOUND TO VISUALIZE STRUCTURES 
The history of echocardiography stands out as a proof for human 
inquisitiveness, curiosity, ingenuity and collaboration across fields of 
science. Ultrasound and doppler are common phenomenon in nature. Bats, 
which are blind mammals, use ultrasound to navigate when flying and form 
a “sonic image” of their environment. The phenomenon was first described 
by L. Spallanzani in YEAR (1729-1799). With the discovery of piezoelectricity 
by the Curie brothers (1), a new era of scientific investigations  emerged. The 
technology was used in reflectoscopes to detect flaws in industrial metals. 
The development of the reflectoscope was accelerated during World War II as 
naval sonar was used for military purpose. The medical use of cardiac 
ultrasound emerged in the 1950s as a result of a fruitful cooperation between 
Inge Edler, a cardiologist, and Carl Hellmuth Hertz, a physicist (Fig.1), both 
from Lund, Sweden (2). At the time, the severity of mitral stenosis was 
evaluated by invasive catheter measurements. Inge Edler aimed to acquire 
accurate measurements of mitral stenosis prior to surgery, for which he 
partnered with Carl Hellmuth Hertz to find a solution. The turning point 
came when Hertz borrowed a reflectoscope from Siemens and performed the 
first echocardiography on himself. He identified a signal that moved with 
cardiac motion. Using M-mode, Edler and Hertz developed the technique 
further to evaluate the mitral valve. Since the introduction of M-mode 
echocardiography, technological development has been sustained with 
consistent improvements in image quality and evolving new modalities. For 
the past decades echocardiography has undergone a particularly dynamic 
phase of development. Today, echocardiography is an integral part of clinical 
cardiology. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Inge Edler  
and Hellmuth Hertz  
(Image from“Sydsvenska 
medicinhistoriska 
sällkapet” photo archive)  
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1.2 DIFFERENT ECHOCARDIOGRAPHIC TECHNIQUES 
1.2.1 One and two dimensional echocardiography 
One-dimensional M-mode echocardiography was the first echocardiographic 
examination performed by Inge Edler and Hellmuth Hertz in 1953. The 
technique was revolutionizing the cardiac examination of patients with mitral 
stenosis. Later, M-mode echocardiography was further developed and was 
used in measuring cardiac dimensions and valvular function. Although, M-
mode echocardiography has an excellent temporal resolution it has the 
disadvantage of being one-dimensional. Later, linear mechanical scanners 
were designed (Fig.2) allowing visualization of a two-dimensional (2D) image 
of the heart. Eventually, sector scanners were developed with further 
improving image quality. 
 
                                 
 
 
 
 
 
 
 
 
 
Figure 2. A multielement transducer that provides an electronic linear scan to represents the first real-time, 2D, 
echocardiography (Left image, with permission: Circulation; 1996; 93 (7): 1321-1327) and a modern sector scanner  
transducer (Right).  
 
With additional improvement of 2D echocardiography and using different 
projections, a comprehensive assessment of cardiac structures and function 
can be achieved. Currently, 2D echocardiography (Fig 3) is the backbone of 
echocardiographic examination allowing evaluation of cardiac geometry, size, 
volume and function. These measurements have tremendous impact on 
management, diagnosis, and prognosis of patients with a variety of cardiac 
disease (3). 
 
 
 
 
 
 
Fig. 3 One-dimensional M-mode 
echocardiography of mitral valve. 
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1.2.2 Doppler echocardiography  
Christian Doppler was the first one who described the Doppler principle in 
1842 when he tried to describe the shift in the color of starlight. The Doppler 
principle implies that frequency of sound waves is higher when the source of 
sound moves toward the observer and lower if the sound source moves away 
from the observer. In the circulatory system, the moving targets are the red 
blood cells (RBC). According to the Doppler effect, the frequency of reflected 
ultrasound waves is higher when the RBCs move toward the transducer and 
lower when they move from the transducer. This frequency shift is used in 
Doppler echocardiography to calculate the velocity of moving red blood cells 
(RBC) in the circulatory system (4). One important limitation of Doppler 
echocardiography is its angle dependency. The maximum velocity of RBCs is 
underestimated if the angle of interrogation (θ) exceeds 20o.  
      
 
Figure 4. Illustration showing the Doppler effect in the circulatory system. RBCs: red blood cells; θ: the angle 
between the ultrasound wave and RBC; C: speed of ultrasound in blood (1540 m/s).  
 
In clinical practice, different modalities of Doppler echocardiography are 
applied for measuring cardiac flow: i) Continuous wave Doppler (CWD). It 
refers to continuous transmission of ultrasound waves towards the red blood 
cells and continuous receiving of the reflected waves from moving red blood 
cells; ii) In the Pulsed wave Doppler (PWD) mode, a single crystal sends and 
receives the reflected ultrasound waves; and iii) Color Doppler flow imaging 
which is based on a rapid, multigated PWD with color coding superimposed 
on the grey-scale 2D image. Red corresponds to flow towards and Blue 
corresponds to flow from the transducer. Doppler echocardiography is the 
backbone of noninvasive assessment of cardiac hemodynamics. 
1.2.3 Doppler tissue imaging 
Doppler tissue imaging (DTI) is an echocardiographic technique that applies 
Doppler principles for visualizing the motion of myocardial tissue, thus 
allowing measurement of myocardial tissue velocities (Fig. 5). In this 
technique, color mode is superimposed on the grey-scale 2D image (5). The 
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color-coding is similar to that of flow Doppler mode with Red moving towards 
and Blue moving away from the transducer. The velocity of myocardial tissue 
is much lower than the velocity of red blood cells, but the amplitude of the 
reflected waves is much higher, thus requiring higher frame rates that are 
usually >100 frame rate/s (6). The recordings can be stored digitally for 
further off-line analysis, which allows measurement of i) tissue velocity; ii) 
Myocardial displacement; and iii) deformation analysis. The myocardial 
velocities can be measured using either Color DTI or pulsed wave (PW) DTI. 
PW-DTI yields high temporal resolution but does not allow analysis of 
multiple myocardial segments simultaneously. Myocardial velocities 
obtained by color DTI are somewhat lower than the velocity measured by PW-
DTI. It has been proposed that PW-DTI might overestimate myocardial tissue 
velocities due to spectral broadening (7). 
 
 
 
 
 
 
 
  
 
 
 
Figure 5. Tissue velocities and cardiac time intervals by color-DTI. AVO: Aortic valve opening; 
AVC: Aortic valve closure; IVCT: Isovolumic contraction time; IVRT: Isovolumic relaxation time; E’ 
and A’: peak early and late annular longitudinal tissue velocity; S: peak systolic annular 
longitudinal tissue velocity. 
 
 
1.2.3.1  Myocardial velocities  
DTI allows measuring peak myocardial tissue velocities (8), and is 
particularly well suited for the measurement of myocardial motion along the 
long axis of the ventricular walls. Myocardial velocities can be measured from 
any segment of the ventricular walls; however the most common sights for 
obtaining systolic and diastolic velocities are at the level of mitral and 
tricuspid annulus in apical four-chamber view. From DTI recordings the 
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following parameters could be obtained: i) IVC (Isovolumic contraction 
phase), a biphasic phase representing slight longitudinal shortening before 
ventricular ejection- IVV (peak myocardial velocity during IVC) ; ii) S (peak 
systolic velocity); measured as the peak positive value during the ejection 
period; iii) IVR (Isovolumic relaxation phase), a negative peak representing 
slight longitudinal elongation before onset of ventricular filling; iv) E´ (Early 
diastolic velocity) measured as a negative diastolic peak. Mitral E´ is a good 
indicator of LV myocardial relaxation. It is one of the main parameters in 
noninvasive assessment of LV filling pressure; and v) A´ (Late diastolic 
velocity), which is measured as a negative diastolic peak and coincides with 
atrial contraction (Fig. 5).  
 
1.2.3.2  Cardiac time intervals 
From Color DTI or Pulsed DTI, different time intervals of the cardiac cycle 
can be obtained (8): i) IVCT (Isovolumic contraction time) corresponds to the 
time interval between A-wave ending of preceding cardiac cycle to S-wave 
beginning of the next cardiac cycle; ii) ET (Ejection time) is measured as the 
duration of S-wave; and iii) IVRT (Isovolumic relaxation time) is measured 
from S-wave ending to the beginning of A´-wave (Fig.5). 
 
1.2.4 Speckle tracking echocardiography  
Speckles are produced by interference, scattering and reflection of 
ultrasound beams in the myocardium. Speckle tracking echocardiography 
(STE) measures myocardial Strain (S) by tracking the speckles throughout 
the myocardium. Hence, strain is a measure of myocardial deformation. STE 
is angle-independent since it relies on tracking the speckles in two 
dimensions throughout the myocardium, in the direction of myocardial fibers 
and not along the ultrasound beam. Strain is defined as the magnitude of 
the changes in the length of myocardial fibers relative to their baseline length. 
It is is calculated as follows S (%) = (Lt - L0)/L0, where Lt is the myocardial 
fiber length at time t and L0 is the myocardial fiber length at baseline (9). 
Myocardial strain rate (SR) is the speed of the changes in the length of 
myocardial fibers. Myocardial strain can be measured along the longitudinal 
fibers (longitudinal strain), circumferential myocardial fibers (circumferential 
strain), and radial fibers (radial strain), (Fig 6). Longitudinal S/SR are 
measured in apical views. Accordingly, circumferential and radial strain are 
be obtained from parasternal short axis views. 
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Fig.6 Assessment of 2-dimensional strain by speckle tracking echocardiography in short axis view 
(above). Orientation of myocardial fibers in the left ventricle and different vectors of myocardial strain 
(below) Reprinted from Gorcsan et al; JACC 2011; 58 (14): 1401-1413, with permission from Elsevier. 
 
 
1.3 LEFT VENTRICLE 
LV myocardium is approximately 2-3 times thicker than RV myocardium. LV 
function resembles a pump, receiving blood from the left atrium (LA) during 
diastole and ejecting blood into the systemic circulation during systole. The 
LV chamber is divided into functionally two major areas: the inflow tract and 
the outflow tract.  
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The inflow tract consists of the mitral apparatus. The LV outflow tract is a 
narrow cavity between the interventricular septum (anteriorly) and the 
anterior mitral leaflet and the aortic orifice (posteriorly).  
 
1.3.1 Left ventricular architecture 
Myofiber orientation of the heart architecture was first described more than 
500 years ago as 2 spiral bands warping around the apical vortex (10). More 
recently, it has been further developed by Torrent-Guasp (11). He described 
a muscular band running from the root of pulmonary artery to the root of 
aorta, forming a helix in the space (Fig.7). The band is forming a basal loop 
consisting of circumferential transverse fibers which occupy the base and the 
upper septum and surrounds both ventricles. It can compresses and rotate. 
A helix which consists of 2 oblique bands; a right-handed or 
counterclockwise coil descending from the basal loop to the apex; and a left-
sided or clockwise coil ascending from the apex to the basal loop (12). The 
myocardial fibers of the descending band contract at the opposite direction 
of the ascending band. This description of the heart architecture has changed 
our view of LV function, which was understood to be compression during 
systole in order to eject blood and dilating during diastole to receive blood. 
The helical model describes several motions of during systole and diastole: i) 
contraction of the basal loop which corresponds to isovolumic systole; ii) 
contraction of descending band leading to the clockwise twisting of the base 
and the counterclockwise twisting of the apex, during this period the 
myocardial fibers are thickening and shortening causing ejection; iii) 
contraction of the ascending band starts after the contraction of the 
descending band and stays longer. Thus when the myocardial fibers of the 
descending band stop contracting the contraction of myocardial fibers of the 
ascending band leads to lengthening of the LV, creating a course for suction 
of blood in early diastole. 
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. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Illustration of dissection of the ventricular myocardial band according to Torrent-Guasp (11). 
apm: anterior papillary muscle; AS: ascending segment; ppm: posterior papillary muscle; Ao: aorta; DS, 
descending segment; LFW, left ventricular free wall; lt: left trigone of the aorta; PA: pulmonary artery; 
ppm: posterior papillary muscle; RFW: right ventricular free wall; rt: right trigone of the aorta. 
(Reproduced with permission from “The Journal of Thoracic and Cardiovascular Surgery”; 2001; 122 
(2): 389-392. 
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1.3.2 Ejection fraction 
EF is the most widely used echocardiographic modality for evaluation of LV 
systolic function. It could be assessed qualitatively (visually) as referred to  
"Eye balling" or can be quantified using the biplane summation of disks 
(modified Simpson's biplane). EF is calculated from LV volumes as (EDV-
ESV)/EDV (9). The principle underlying Simpson's biplane rule is that the 
LV volume is the summation of  volumes of a stack of elliptical discs. Apical 
four-chamber and 2-chmaber views are acquired to asses LV volumes. In 
order to assess LV volumes the interface between the myocardium and the 
LV cavity is traced and the tracing is closed at the level of mitral annulus. 
The volume calculation is based on the assumption that LV is elliptical-
shaped. Despite several limitations, it is best validated as a prognostic 
marker. Several studies have confirmed EF as a predictor of outcomes in 
heart failure (HF) and as a predictor of sudden cardiac death (13) 
 
1.3.3 Systolic myocardial velocities  
Systolic myocardial velocities at the level of mitral annulus have been shown 
to be a good measure of myocardial longitudinal function which are well-
correlated with LVEF and LV dp/dt (14). Tissue velocities can be used to 
quantify myocardial function in patients with CAD however, with important 
limitations. In mild CAD, the velocity of "S" is decreased. However, in 
moderate CAD "S" remains positive. On the other hand, it has been shown 
that myocardial velocities are more appropriate markers of regional 
myocardial function in severe ischemia (15). In normal ventricles, IVC is 
dominated with a brief positive spike. During severe ischemia, IVC spike 
becomes negative. Additionally, it has been shown that, in patients with 
diastolic heart failure, the amplitude of mitral annular peak systolic velocity 
is lower compared to age-matched healthy controls (16). Several studies have 
confirmed the prognostic role of systolic myocardial velocities in patients with 
heart failure and CAD (17).  
 
1.3.4 Global Longitudinal strain 
Global longitudinal strain (GLS) is the most commonly used strain-based 
modality in everyday clinical practice. GLS can be assessed using DTI (18)or 
STE (19). However, assessment of GLS using STE is preferred since STE is 
angle-independent and DTI is angle-dependent. (20). GLS is calculated as an 
average of regional longitudinal strain measured in 3 standard apical views 
namely, apical long axis, four-chamber and two-chamber views (21). One of 
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the limitations of the current technique in assessment of  strainthe relatively 
high variability between different vendors (20). The normal reference values 
for GLS can vary depending on which vendor is when assessing GLS (22).  
 
1.3.5 Left ventricular diastolic function 
LV diastolic function was first evaluated invasively using the rate of LV 
pressure reduction, LV relaxation time constant, and measurement of 
myocardial and chamber stiffness (23). Currently, noninvasive 
echocardiographic assessment of diastolic function is used in everyday 
clinical practice (Fig.8). It incorporates PW-Doppler of mitral inflow, mitral 
annular myocardial velocities assessed by PW-DTI, LA volume, and 
measurement of pulmonary systolic artery pressure (PASP). The current 
guidelines for evaluation of diastolic function also take EF into consideration 
(24). One of the aims of the current guidelines is echocardiographic 
estimation of LV filling pressure.  
           
Figure 8. Evaluation of LV diastolic function; mitral inflow pattern (left); E´ velocity (right): E and A: 
early and late mitral inflow velocity; E’ and A’: peak early and late annular longitudinal tissue velocity; 
S: peak systolic annular longitudinal tissue velocity. 
 
1.3.6 Cardiac time intervals a historical perspective 
In the late 1960s indirect measurement of systolic time intervals was 
performed by simultaneous recordings of (1) electrocardiogram (ECG); 2) 
phonocardiogram, from the area with the loudest aortic component of the 
second heart sound; and (3) indirect carotid pulse tracing, using a funnel-
shaped sensing head connected to the transducer by air-filled tube, and 
manually held over one carotid artery (25). The total electromechanical 
systole (QS2) was defined as the interval from the onset of QRS on the ECG 
to the closure of aortic valve (S2) as reflected as the second heart sound on 
the phonocardiogram. Ejection time (ET) was measured from the beginning 
upstroke to the trough of incisura of carotid pulse tracing. The interval 
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between the first (S1=closure of AV valves) and the second heart sound (S2 
=closure of the semilunar valves) was also measured-S1S2 (Fig. 9). The 
following time intervals were calculated: Pre-ejection period (PEP)=QS2 -ET 
and Isovolumic contraction time (ICT)=S1S2 -ET were calculated (26). 
Subsequently, high-speed recordings of aortic valve movements by 
echocardiography was used as an alternative method for determination of the 
systolic time intervals (Fig. 9) Several studies demonstrated that diminished 
ET, a high ratio of pre-ejection period (PEP)/ET, and a prolonged isovolumic 
relaxation time (IVRT) were associated with left ventricular dysfunction (27, 
28). 
 
                       
 
 
 
 
 
 
 
 
 
Figure 9. Measuring systolic time intervals by simultaneous carotid arterial pulse tracing, ECG and 
phonocardiogram (left. Reproduced with permission from Weissler AM. et al Circulation. 1968; 37 
(2):149-59). Determination of systolic time intervals using phonocardiogram, ECG, M-mode 
echocardiography of aortic valve, and indirect carotid arterial pulse tracing (right). PEP: Pre-ejection 
period; QS2: total electromechanical systole; LVET: left ventricular ejection time; S1S2: heart sounds 
interval; Q-1: interval from onset of QRS to first heart sound; ICT: isovolumic contraction time 
(Reproduced with permission from Miltiadis A. et al; Circulation; 1975; 51(2):114-17). 
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1.3.7 Myocardial performance index a historical perspective 
Earlier studies had mainly focused on measuring systolic time intervals as 
described previously. The myocardial performance was quantified using the 
ratio of PEP/ET (27, 29). Using the ratio would overcome limitation of the 
cardiac time intervals in the presence of arrhythmia. Further, investigators 
subdivided the PEP into the electromechanical delay and ICT which was 
associated with contractility (23). It was technically difficult and complicated 
to obtain the Isovolumetric time intervals before the era of Doppler 
echocardiography. However, with the evolvement of echocardiography, the 
time intervals of the cardiac cycle could easily be obtained. ICT and 
Isovolumetric relaxation time (IVRT) have long been used in assessment of 
systolic- and diastolic function, respectively (30, 31). 
It had been demonstrated that the ratio of (PEP)ICT/ET provides a useful 
index which correlates well with stroke volume, cardiac output and fractional 
shortening (26). Later, it was shown that an index of myocardial relaxation 
is frequently prolonged in patients with cardiac disease (32). Subsequently, 
Mancini et al (28) demonstrated that isovolumic index, which they described 
a ratio of the sum ICT and IVRT divided by ET, is a sensitive marker of 
myocardial dysfunction (33). The index was assessed by simultaneous 
measurement of carotid artery pulse tracing and mitral M-mode 
echocardiogram . 
1.3.8 Myocardial performance index by Doppler flow echocardiography 
In 1995, Tei and his colleagues introduced a new Doppler index of combined 
systolic and diastolic myocardial performance (34). Patients with dilated 
cardiomyopathy with moderately and severely reduced EF were compared 
with healthy subjects. PW-DTI of mitral inflow pattern and PW-DTI of left 
ventricular outflow pattern was used for measuring different cardiac time 
intervals. Different time intervals were measured. Then the “new  index of 
myocardial performance”  was assessed as the  ratio of (ICT+IVRT)/ET (34); 
(Fig 10). Ventricular dysfunction results in the prolongation of both ICT and 
IVRT and in a reduction of ET. Therefore, myocardial performance index is 
increased in patients with ventricular dysfunction (35). Tei et al showed that 
the normal range for LVMPI was (0.39 ± 0.05) in healthy persons; (0.59 ± 0.1) 
in patients with moderate heart failure and (1.06 ± 0.24) in patients with 
severe heart failure (23). Subsequent studies from the same investigators 
showed good correlation between the MPI and invasive measurements of 
systolic LV performance (peak +dP/dt) and diastolic LV performance (peak -
dP/dt), and tau by left ventricular catheterization (23). 
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   Figure 10. Assessment of left ventricular myocardial performance from  
   mitral inflow and left ventricular (LV) outflow.  
 
Similarly, right ventricular index of myocardial performance (RIMP) can be 
assessed using Doppler recordings of tricuspid inflow pattern and right 
ventricular outflow pattern. (Fig. 11) 
 
 
 
 
 
 
 
 
 
          Figure 11. Assessment of right ventricular index of myocardial performance (RIMP) 
          using tricuspid inflow and right ventricular (RV) outflow. ET: Ejection time. 
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1.3.9 Myocardial performance index by Doppler tissue echocardiography 
Recently assessment of MPI by color DTI or pulsed DTI (Fig.) has evolved, 
allowing measurement of all time intervals from the same heart cycle (36). 
However, assessment of MPI by Doppler flow echocardiography has the 
disadvantage of measuring time intervals from two different heart cycles, 
which could compromise accuracy in significant arrhythmias and varying 
RR-interval on ECG. Conventional MPI, assessed by pulsed-Doppler, is 
preload-dependent while MPI assessed by DTI is less dependent in preload 
(37, 38). 
Additionally, assessment of MPI by pulsed DTI is accurate and reproducible 
because it has high temporal resolution and is easy to obtain. A good 
correlation between MPI obtained with DTI and MPI determined by pulsed 
DTI has, previously been confirmed by several studies. Accordingly, a good 
correlation between tissue Doppler MPI and pulsed-Doppler MPI has been 
demonstrated(39). Although only mild agreement between PW-DTI and 
conventional pulsed-Doppler MPI has been shown, high accuracy of both 
methods in detection of ventricular dysfunction has been demonstrated. 
Accordingly, higher cut-off values for MPI assessed by PW-DTI has been 
suggested (40). More recently, assessment of MPI by DTI M-mode through 
mitral valve leaflets has evolved (41), which has shown to have strong 
association with invasive measurements of cardiac function (42). 
 
1.3.10 Cardiac state diagram 
Cardiac State Diagram (CSD), (43) is a new modality for displaying different 
cardiac events and cardiac time intervals in a simple and intuitive graphical 
overview (Fig.12). CSD is assessed by using a software (GHLab), (44). The 
data from color-DTI recordings of the LV/RV is imported to GHLab and 
processed by the Software. The software processes and adopts different 
parameters, such as, acceleration, velocity, and pattern recognition in order 
to create CSD (Fig13). CSD allows visualization of various cardiac mechanical 
events as a circular diagram. CSD displays several different parameters, such 
as tissue velocity, duration of time intervals, stroke lengths of the 
atrioventricular (AV)-piston, flow velocities, deformation information, and 
ECG. CSD represents a graphical view of these parameters of cardiac events. 
The diagram can be constructed with one outer circle (LV) or two outer circles 
corresponding to LV and RV demonstrating, the global timing of different 
time-events of cardiac cycle, where a complete circle corresponds to one 
cardiac cycle. The displacement of the AV-piston at the basal level of cardiac 
walls is displayed as a black circle in the middle of the diagram, 
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demonstrating information about the associated segments, strain, and strain 
rate. The beginning of the cardiac cycle corresponds to atrial contraction and 
the end with the slow filling. In this way the cardiac cycle is harmonize with 
the events in ECG signal activity, where normally the P-wave is the first 
activity seen in the ECG. 
 
 
 
 
 
 
 
 
 
 
 Figure 12 Cardiac state diagram. Outer circle represents duration of different cardiac time intervals of 
one cardiac cycle in one basal LV segment. The inner red circle shows strain information. The black 
circle indicates the displacement of the AV-piston in different segments at basal level of the LV. T1-T20 
= Time marks during the cardiac cycle. (Reproduced with permission from Jonas Johnson) 
 
 
 
 
 
 
 
 
 
   
 Figure 13. Illustration of velocity trace of different time events (T1-T20) of one cardiac cycle MPn = 
Main phase. The color coding corresponds to the same phases as the image above. (Reproduced with 
permission from Jonas Johnson) 
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1.4 RIGHT VENTRICLE 
RV is located in the chest behind the sternum and anterior to the left ventricle 
(45) comprising mostly of a thin muscular layer wrapping around the left 
ventricle. In frontal plane, it is triangular-shaped and in cross-sectional 
plane, crescent-shaped. Anatomically it consists of 3 distinct parts: i) the 
inflow consisting of tricuspid valve apparatus, ii) apex, and iii) the outflow 
consisting of smooth muscle (46). Imaging of RV with 2D echocardiography 
is hampered owing to its location in the chest and its anatomical 
characteristics . Three-D echocardiography is overcoming many of the 
limitations of 2D echocardiography and is a promising modality in 
assessment of RV geometry and function. 
 
1.4.1 Right ventricular size 
Due to the anatomical complexity of the RV, using 2D echocardiography 
images from multiple acoustic windows should be acquired and measured in 
order to obtain an comprehensive assessment of RV size (9). Linear end-
diastolic measurement of proximal- and distal right ventricular outflow tract 
(RVOT) in parasternal views and basal and mid-ventricular measurement of 
RV end-diastolic diameter in apical views have been recommended. In 
addition end-diastolic and end-systolic measurements of RV area in RV 
focused apical views by manually tracing the endocardial border has been 
recommended (9). 
 
1.4.2 Right ventricular function 
Complexity of RV anatomy renders difficulties in the assessment of RV 
function. Therefore, the latest guidelines recommend using a number of 
surrogate echocardiographic parameters in evaluation of RV function (9) 
Further, the majority of RV systolic parameters are load dependent (47). 
 
1.4.3 Right ventricular ejection fraction 
Assessment of right ventricular ejection fraction (RV EF) by 2D 
echocardiography has important limitations, and a number of studies report 
lack of accuracy (48). Although in comparison with cardiac magnetic 
resonance (CMR), 3DE underestimates RV volumes and EF, evaluation of RV 
EF using 3D echocardiography is recommended because it has been shown 
to be more accurate and reproducible (49). Since RV EF is reflecting an 
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integrated interaction between RV contractility and loading conditions, it 
cannot be considered a reliable parameter in quantifying RV systolic function 
in patients with pressure or volume overload. RV EF has been reported as an 
independent predictor of mortality in patients with heart failure (50). 
 
1.4.4 Tricuspid annular plane systolic excursion 
In systole, tricuspid annulus will normally descend 1.5-2.4 cm towards apex. 
This longitudinal motion of tricuspid annulus can be displayed using M-
Mode echocardiography through lateral tricuspid annulus in apical four-
chamber view. Accordingly, on the M-mode recordings the magnitude of the 
displacement of the lateral tricuspid annulus is measured and the tricuspid 
annular plane systolic excursion (TAPSE) is obtained. Strong correlation 
between TAPSE and parameters of global RV function as radionuclide-
derived RV EF and CMRI-derived RV EF has been reported(51, 52). TAPSE is 
one-dimensional with the assumption that the regional, longitudinal 
displacement of the basal RV segment represents global RV function. Since 
it is a one-dimensional measurement relative to transducer it can over- or 
underestimate RV function due to overall heart motion (53). TAPSE is load 
dependent and the change in severity of functional tricuspid regurgitation 
(TR) may significantly affect its results. Previous studies have demonstrated 
association between TAPSE less than 1.5 cm and poor prognosis after acute 
myocardial infarction (54). 
 
1.4.5 Tricuspid annular peak systolic velocity 
Tricuspid lateral annular peak systolic velocity (RVS) is measured using color 
DTI or PW-DTI at the level of tricuspid lateral annulus with the curser parallel 
to the annulus. RVS is easy to obtain, reproducible and correlates well with 
other parameters of global RV function (55). Similar to TAPSE, RVS is a one-
dimensional surrogate of RV function, measuring the velocity of longitudinal 
motion of RV free wall at basal segment relative to the position of the 
transducer. As such, it is influenced by the overall cardiac motion and can 
over- or underestimate RV function. Further, RVS is influenced by age and 
is reduced with increasing age (56). A number of studies have acknowledged 
a good correlation between TAPSE and RVS (55). RVS less than 9.5 is 
suggestive of RV dysfunction.  
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1.4.6 Fractional area change 
Fractional area change (FAC) is a good measure of global RV performance, 
which is well-correlated with MRI-derived RV EF (57) and associated with 
outcomes in a variety of cardiovascular diseases (58, 59). In order to assess 
RV FAC, the RV endocardial border is traced manually and end-diastolic and 
end-systolic areas are obtained in RV-focused apical four-chamber view to 
calculate RV FAC (%) = 100 x (RV EDA - RV ESA)/RV EDA. While tracing, 
care must be taken to include trabeculations in the cavity and avoid apical 
foreshortening. Calculation of RV FAC requires good RV images with good 
endocardial delineation and as a measure of overall RV systolic function does 
not include RVOT (contributing to 25-30% of RV volume). RV FAC less than 
35% indicates RV systolic dysfunction. 
1.4.7 Right ventricular strain and strain rate 
RV longitudinal strain is measured as the percentage of systolic, longitudinal 
shortening of RV free wall from base towards the apex, and RV strain rate is 
the rate of the shortening. RV longitudinal strain can be measured using 
either DTI or STE (60). Although, the correlation between the methods is 
moderate, both techniques have shown to be accurate and feasible in 
discriminating physiology from pathology (61). DTI-derived RV strain renders 
a number of limitations as: angle-dependency, large longitudinal motion of 
RV free wall requiring high frame rates, and influenced by age and heart rate. 
There are a number of issues in regard to  measuring strain by STE. There 
are inconsistencies in measuring and reporting RV LS. While in some studies 
only 3 segments of RV free wall are included, in other studies an additional 
3 segments of interventricular septum are also included. There are also 
inconsistencies in normative values, since the normal values are strongly 
intervendor-dependent. However, assessment of  RV strain is evolving as 
robust and feasible in quantification of RV mechanical function as the body 
of evidence for its prognostic value in various cardiac disease (heart failure 
(62), AMI (63), amyloidosis (64), pulmonary hypertension (65)) is growing. The 
threshold of RV strain is set at -20% by the recent guidelines (9). 
1.4.8 Right ventricular diastolic function 
Assessment of RV diastolic function is not part of clinical evaluation of RV 
function. While there is a body of evidence on diagnostic and prognostic 
implications of RV systolic dysfunction, there are only a few studies 
addressing the prognostic implications of RV diastolic dysfunction (66).  
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1.4.9 Right ventricular index of myocardial performance 
As previously described, RIMP is an estimate of global RV performance 
combining systolic and diastolic time intervals of cardiac cycle. Several 
techniques for assessment of RIMP are available. However, pulsed spectral 
Doppler (PW) of the tricuspid inflow and RV outflow, and DTI of the lateral 
tricuspid annulus are the most common methods. In patients with significant 
arrhythmias, using pulsed Doppler for calculation of is not recommended 
given the significant RR variation in inconsecutive cardiac cycles. This 
limitation is overcome in calculating RIMP by DTI since a single RR-interval 
is used. RIMP >0.43 by PW Doppler and >0.54 by DTI indicates overall RV 
dysfunction. 
1.5 IMPACT OF ISCHEMIA AND REVASCULARIZATION ON 
MYOCARDIAL FUNCTION 
The tight association between coronary blood flow supply, myocardial oxygen 
demand, and contractile performance of cardiac myocytes is the fundamental 
principle of cardiac physiology. Further, a close coupling between regional 
coronary blood flow and state of contractile function of cardiac myocytes, 
known as perfusion-contraction matching, has been demonstrated. It is 
known that reduced coronary blood flow results in decreased myocardial 
contractile function. Depending on the severity and duration of flow 
reduction, decreased contractile function might be reversible or permanent. 
When the coronary blood flow i severely reduced, and persists for more than 
20 minutes, the contractile function of the myocardium may irreversibly be 
damaged due to development of necrosis. However, when myocardial 
ischemia is brief or moderate myocardium remains viable and the contractile 
dysfunction can be reversed upon reperfusion/revascularization. This 
condition of chronic adaptive reversible reduction in contractile function is 
known as myocardial hibernation. However, contractile recovery may require 
considerable time despite restoration of adequate coronary blood flow supply. 
This condition of flow-function mismatching is known as myocardial 
stunning. On the other hand, if the myocardial contractile dysfunction is due 
to fibrosis then no recovery after revascularization therapy is to be expected. 
 Several imaging modalities including DSE are commonly used in the 
assessment of myocardial viability, and have the ability to predict recovery of 
function after revascularization.  
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1.6 BNP 
B-type natriuretic peptide (BNP) was first identified in brain extracts, thus it 
is also known as Brain natriuretic peptide. BNP is secreted from ventricular 
myocardium in response to an increase in wall stress pressure or volume-
overload (67). After synthesis BNP is cleaved to proBNP. When in the 
circulation, proBNP is cleaved into the active portion of BNP and inactive 
amino-terminal NT-proBNP. The half-time of BNP is 20 min whereas the half 
life of NT-proBNP is 120 min (68). BNP and NT-proBNP are expressed in 
pg/ml or µmol/L. The conversion factor of BNP is 1pg/ml= 0.289 µmol/L, 
and the conversion factor for NT-proBNP is 1pg/ml= 0.118 µmol/L (68). The 
physiological effects of BNP are many and include peripheral vasodilatation, 
as well as inhibition of renin-angiotensin-aldosterone system (68). Cardiac 
conditions such as (AF; pulmonary embolism) or some non-cardiac 
conditions such as (renal impairment) will result in increased circulatory 
BNP-levels due to increased volume or pressure overload on cardiac 
chambers. BNP levels increase with age and are likely to reduce in obese 
patients (69). It has been demonstrated that BNP and NT-proBNP have 
similar diagnostic performance in patients with heart failure, patients with 
asymptomatic left ventricular dysfunction and in patients with renal failure. 
BNP and NT-proBNP are used as powerful diagnostic markers in the 
management of patients presenting with heart failure symptoms and can be 
used as a complementary method to guide therapy in heart failure (70). 
According to recent ESC guidelines, heart failure is unlikely if BNP<35 pg/ml 
or NT-proBNP<125 pg/ml . Similarly, in patients with suspected acute heart 
failure the diagnosis is unlikely if BNP<100 pg/ml and/or NT-proBNP<300 
pg/ml (71). 
Further, several studies suggest that BNP and NT-proBNP are valuable 
prognostic markers of death and cardiovascular events in patients with heart 
failure, CAD and valvular heart disease (72-74). 
In conclusion, both BNP and NT-proBNP are valuable diagnostic and 
prognostic biomarkers reflecting increased myocardial wall stress 
independent of underlying specific pathology. Thus, they reflect cardiac 
disease in general and not a specific pathology.  
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2 AIMS 
 
STUDY I 
In patients with coronary artery disease (CAD), the goal of surgery is to relieve 
ischemia and to improve myocardial function. We sought to evaluate the 
effects of CABG on LV function in patients with established ischemic heart 
disease. In addition to other conventional methods we addressed an objective 
measurement of cardiac performance after CABG by using time intervals in 
MPI assessed by PW-DTI of four different sites around the basal portion of 
the LV.  
STUDY II 
In this study, we aim to characterize the impact of CABG on RV function in 
patients with advanced CAD undergoing isolated CABG. The impact of CABG 
on RV function was assessed using conventional parameters as TAPSE and 
RVS as compared to RIMP as an estimate of global RV performance. Further, 
the effect of CABG on RV function during DSE was evaluated. 
STUDY III 
This is predefined post hoc analysis of a single-center randomized trial. We 
seek to compare changes in both load dependent and independent metrics of 
RV performance in patients treated with full sternotomy AVR vs. MIAVR. In 
this study, we aimed to study alterations in RV longitudinal function, RV 
global function, and RV contractility following AVR vs MIAVR. 
STUDY IV 
In this study, we evaluate the independent role of postoperative BNP, 
assessed in a stable clinical setting 3 months after CABG for predicting long-
term outcomes following isolated, primary CABG. Further, in a 
subpopulation of patients we evaluated the correlation between LV-MPI, 
RIMP, and BNP respectively as markers of myocardial function. 
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3 MATERIALS AND METHODS 
3.1 PATIENT POPULATION (STUDY I, II & IV) 
From May1995 to February 2001, 746 patients were admitted to the hospital 
due to angina and were assigned to CABG based on findings on coronary 
angiography and according to existing guidelines. Patients with (i) atrial 
fibrillation; (ii) severe valvular heart disease; (iii) pacemaker; (iv) recent 
myocardial infarction (within 4 weeks); and (v) previous CABG were excluded. 
This left, 99 patients to be included in the study. All the included patients 
underwent blood tests, Bicycle exercise test, comprehensive 
echocardiography, and Dobutamine stress echocardiography at the time of 
initial angiography (Fig 14). In a subpopulation of 46 patients, Doppler Tissue 
Imaging (DTI) echocardiography was also performed (Table 3). Postoperative 
clinical follow-up was performed 3 months after CABG. At that point all the 
tests which were performed upon inclusion, including a follow-up 
angiography, were performed again at follow-up. In the patients with DTI, 
LV-MPI and RIMP were assessed respectively at rest and at peak DSE both 
before CABG and after CABG. Generally speaking high values of LV-
MPI/RIMP indicate myocardial dysfunction, while low values indicate good 
myocardial performance. 
The patients were followed-up by send-out questionnaires and additionally 
through medical records for a median of 5 years (3-7 years) after receiving 
CABG (Fig.14). 
 
Figure 14. Chart flow of studies (1, II, IV) showing the number of patients evaluated in each setting,    
before CABG, 3 months after, and 5 years after CABG. CABG: coronary artery bypass grafting. 
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3.2 ECHOCARDIOGRAPHY (STUDY I, II & IV) 
Echocardiography examination was performed with patients lying on their 
left lateral side and using a Sonos 5500 (Hewlett-Packard, Andover, MA, 
USA). A complete 2-D and Doppler examination was performed.  
 
3.2.1 Measurement of cardiac chamber Size 
From the parasternal long axis view, linear internal dimensions of the LV  
were measured at end-diastole (LVEDD) and end-systole (LVESD). LV 
volumes were obtained from apical four- and two-chamber view, at end- 
diastole (LVEDV) and end-systole (LVESV) using Simpson’s biplane. 
Basal RV linear dimension (RVD1) was measured as the maximal transversal 
dimension in the basal one-third of RV inflow at end-diastole. Proximal RV 
outflow (RVOT prox) was obtained in parasternal long-axis view and 
measured at end-diastole from the anterior RV wall to the interventricular 
septal-aortic junction. 
 
3.2.2 Left ventricular ejection Fraction 
LV systolic function was quantified by ejection fraction (LVEF) using 
Simpson’s biplane method from apical four- and two-chamber views: LVEF 
(%)= 100 x (LV EDV-LV ESV)/LV EDV.  
3.2.3 Left ventricular diastolic function  
From apical four-chamber view, PW-Doppler of mitral inflow was obtained. 
Then mitral peak early (E), and late inflow velocity (A) were measured and 
mitral E/A ratio was calculated. Peak early systolic tissue velocity of the 
septal wall at the level of mitral annulus was measured using PW-DTI 
Accordingly, the ratio of E/E´ was calculated. 
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3.2.4 Right ventricular systolic function 
M-mode recordings of RV free wall at the level of tricuspid annulus  were 
obtained and TAPSE was measured as the maximum of displacement of the 
RV lateral annulus (Fig. 15). RVS was measured as the peak systolic velocity 
of lateral tricuspid annulus using PW-DTI. 
 
 
Figure 15. Assessment of tricuspid annular systolic excursion (TAPSE) by M-mode (Left), and 
measurement of right ventricular peak systolic velocity (RVS) using pulsed Doppler tissue imaging. 
 
3.2.5 Right ventricular diastolic function  
Diastolic RV function was quantified by calculating the tricuspid E/A ratio. 
From apical four-chamber view, PW-Doppler of tricuspid inflow was obtained, 
and tricuspid peak early inflow velocity (E), tricuspid peak late inflow velocity 
(A) was measured and subsequently tricuspid E/A ratio was calculated. 
 
3.2.6 Cardiac time intervals and myocardial performance index by pulsed 
Doppler tissue imaging  
Cardiac time intervals were assessed using PW-DTI recordings which were 
obtained online using a variable frequency phased array transducer (2.0-4.0 
MHz), a low filter wall setting (50 Hz), and a small sample volume of 1.7 mm. 
Accordingly, the gain was optimized. PW-DTI images of the septal, lateral, 
inferior, and anterior walls of the LV and RV free wall were obtained at the 
level of mitral annulus and at the level of lateral tricuspid annulus from 
apical 4-chamber view respectively. The subsequent analyses were performed 
from the digitally stored PW-DTI recordings. The time interval between 
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cessation (A´) and the beginning of the (E´) was measured as the total 
combined duration of  (ICT + ET + IVRT). The ET was measured as time 
interval between onset and cessation of the S-wave. MPI was calculated as 
(ICT + ET + IVRT) – ET / ET . Global LV MPI was calculated as an average of 
MPI from those LV sites as mentioned above. Accordingly, RIMP was 
calculated by the same way at the lateral tricuspid annulus.  
3.2.7 Dobutamine stress echocardiography 
DSE was performed using a standard protocol at the Echo-lab. Briefly, the 
dobutamine infusion started at a starting dose of 5 µg/kg/min and was 
increased every 3 minutes up to a maximum dose of 40 µg/kg/min. If 
required, intravenous atropine sulfate up to 1 mg was also in addition 
administered. The test was terminated whenever the endpoints were reached 
as recommended by the European Association of Echocardiography (75). 
WMSI was calculated using a 16-segment model. Segmental wall motion 
score was defined as follows: 1=normal/hyperkinetic; 2=hypokinetic; 
3=akinetic; 4=dyskinetic; 5=aneurysm. The WMSI was calculated as the sum 
of scores divided by the number of segments visualized. An ischemic 
response was defined as development of new wall motion abnormality in at 
least 2 adjacent segments of LV wall. 
 
3.3 CORONARY ANGIOGRAPHY 
Coronary angiography was performed using the standard protocol of the 
angiography lab. All angiographic images was interpreted by an experienced 
interventional cardiologist. Any stenosis of ≥ 50% in coronary arteries or their 
major branches was considered significant. 
 
3.4 BICYCLE EXERCISE STRESS TEST 
Upright bicycle exercise stress tests were completed using a stationary 
bicycle and the 10-point Borg scale (76). Conventional clinical and ECG 
monitoring was used during the test. The peak heart rate, systolic blood 
pressure, respiration, symptoms and estimated work load were recorded for 
each test.. The test was ended using endpoints recommended at the lab(77)  
The work load was measured as watts.  
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3.5 BNP 
Blood samples were obtained from antecubital vein using vacutainer 
equipment and without implying stasis. The samples were prepared 
immediately. The plasma samples were stored at -80 C for future analysis. 
The BNP was measured using immuno radiometric assay (IRMA). In this 
method, two monoclonal antibodies react against two sterically distinct 
portions of the BNP molecule. The first is "coated" on a bead, while the other 
is tagged with 125 [I] and used as a tracer. The BNP molecule present in the 
sample is bound between the two antibodies and thus anchored to the 
antibody associated with the bead. Unbound tracer is eliminated in the 
following washing steps, and the bead only retains the antibody / antigen / 
tracer complex. The amount of radioactivity bound to the solid phase is 
proportional to the amount of BNP present in the sample. 
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3.6 PATIENT POPULATION (STUDY III) 
The CMILE ( Cardiac Function after Minimally Invasive Aortic Valve 
Implantation) study was designed as a randomized, single-center, open label 
study. Adult patients assigned to surgical aortic valve replacement at 
Karolinska University Hospital in Stockholm, Sweden were eligible for 
inclusion into the study. Patients were included in the study between October 
2013 and July 2015. Patients were excluded if they had (i) reduced left 
ventricular Ejection Fraction (LVEF) <45%); (ii) previous cardiac surgery; (iii) 
concomitant other severe valvular heart disease; (iv) coronary artery disease 
(CAD) requiring surgical intervention; and/or (v) urgent or emergency surgery 
(Fig. 16). Coronary angiography for evaluating coexisting CAD was performed 
prior to surgery. Echocardiography was performed within one week before 
surgery and 40 days post-surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 16. Chart flow of patients in study III, AVR: aortic valve replacement surgery, MIAVR: minimally 
invasive aortic valve replacement surgery. 
56 patients were eligible  
1 converted to AVR 
intraoperatively 
20 (50%) were assigned to 
MIAVR 
16 did not give 
consent 
40 patients completed 
randomization 
20 (50%) were assigned to 
AVR 
19 of 19 (100%) completed  
postoperative 
echocardiography  
 
19 of 19 (100%) completed  
postoperative 
echocardiography  
 
          2 died  
postoperatively 
Crossover to 
AVR  
214 patients met inclusion criteria 
for aortic valve replacement 
surgery 
158 excluded due to  
LVEF <45% (n=40) 
Previous cardia surgery 
Urgent surgery (n=10) 
Participation in another 
study 
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3.7 SURGICAL TECHNIQUES (STUDY III) 
3.7.1 Minimally invasive aortic valve replacement surgery (MIAVR) 
MIAVR was performed via a J-shaped upper partial ministernotomy 
approach. A skin incision of approximately 6 cm in the midline over the upper 
part of the sternum was performed (Fig 17). A partial J-shaped skin incision 
was extended into the third intercostal space. A small vertical pericardial 
incision anterior to ascending aorta was performed, and subsequently the 
aortic valve was exposed. Cardiopulmonary bypass with central arterial and 
central or peripheral venous cannula was established. Subsequently, 
antegrade custodial cardioplegia solution was administered. CE marked 
mechanical or bioprosthetic aortic valves were implanted. The bioprosthetic 
valves could be conventional stented, or sutureless bioprostheses. The 
pericardial incision was closed at the end of procedure. 
 
3.7.2 Conventional full sternotomy aortic valve replacement surgery (AVR) 
The heart was exposed through full median sternotomy (Fig 17). A complete 
pericardial incision was performed. Cardiopulmonary bypass was 
established. Antegrade and/or retrograde cold blood cardioplegia was 
administered. CE marked mechanical or bioprosthetic aortic valves were 
implanted. The pericardial incision was not closed at the end of procedure. 
 
Figure 17. Illustration of Edwards showing conventional aortic valve replacement surgery (AVR), (left) and 
minimally invasive aortic valve surgery (MIAVR), (right).  
Images provided courtesy of © 2018 Edwards Lifesciences Corporation. All rights reserved 
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3.8 ECHOCARDIOGRAPHIC MEASUREMENTS (STUDY III) 
All echocardiography examinations were performed on a Vivid E9 (GE, 
Healthcare, Horten, Norway). The images were digitally stored. All 
subsequent analyses were performed off-line on an EchoPAC station , version 
201 (GE Vingmed Ultrasound AS, Horten, Norway). All linear measurements 
and LVEF were assessed as previously described. 
 
3.8.1 Left ventricular global longitudinal strain  
Speckle tracking Echocardiography was applied to assess LV-GLS and LV-
GLSR. The image quality and the gain setting was optimized. The depth of 
cine loops were adjusted in order to achieve a minimum frame rate 50/s. Off-
line analysis was conducted with dedicated, commercially available software 
for speckle tacking  2D-strain analysis on the EchoPAC (GE, version 201, 
US). LV GLS was measured in three standard apical LV views and averaged. 
Measurements started in the apical long axis view, then apical four-chamber 
view and ended with apical two-chamber view. An automatic estimate of 
aortic valve closure was used by the software to predefine end systole. The 
software used an ECG-Derived time marker for defining end systole which 
was set as the end of T-wave on ECG. The software automatically calculated 
segmental strain and GLS (Fig 18). 
Figure 18. Displaying assessment of left ventricular global longitudinal strain. 
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3.8.2  Right ventricular longitudinal function  
TAPSE was obtained as previously described. RVS was assessed using 
GHLab (Gripping Heart AB, Stockholm) software (43) and measured as the 
maximal myocardial velocity during right ventricular ejection (Fig. 19). 
 
 
 
 
 
 
 
 
 
Figure 19. Position of ROI on color-DTI echocardiogram (left), measuring RVS by CHLab (right). 
 
3.8.3 Fractional area change 
RV endocardial border was traced manually at end-systole and at end-
diastole. The tracings were applied manually from the lateral tricuspid 
annulus along the RV free wall to the apex and along the interventricular 
septum back to the medial tricuspid annulus. Trabeculations, papillary 
muscles and moderator band were included in the RV cavity area. RV FAC 
(%) was calculated: 100 x (EDA-ESA)/EDA (Fig.20). 
 
 
 
 
 
 
 
 
 
 
Figure 20. Assessment of right ventricular (RV) fractional area change (FAC)  
     by 2D echocardiography. 
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3.8.4 RV longitudinal strain and Strain rate 
Speckle tracking Echocardiography was applied on RV-focused four-
chamber view to assess RV-LS and RV-LSR. The depth of cine loops was 
adjusted in order to achieve a minimum frame rate 50/s. The gain setting 
was optimized. Off-line analysis of the RV apical four-chamber view was 
conducted with dedicated, commercially available software for speckle 
tacking 2D-strain analysis on the EchoPAC (GE, version 201, US). The 
endocardial border of the RV free wall was marked and the size of the ROI 
was adjusted in order to limit it to the myocardium. The tracings were 
manually corrected whenever needed. The RV free wall was divided into three 
segments: basal, mid, and apical. The software automatically calculated 
segmental and global RV-LS and global RV-LSR through out cardiac cycle 
(Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Assessment of right ventricular strain (A) and strain rate (B). 
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3.8.5 Cardiac time intervals and myocardial performance index by GHLab 
The traces of myocardial longitudinal motion from the Tissue Doppler 
Imaging (TDI) recordings were imported to software called GHLab (Gripping 
Heart AB, Stockholm, Sweden), (78), where the software automatically 
identified the different phases of the cardiac cycle and myocardial velocities. 
The software identified the different mechanical cardiac time events using 
the Dynamic Adaptive Piston Pump (DAPP) principle that describes the heart 
as a mechanical pump controlled by its inflow . In this model, the movement 
of the atrioventricular-plane initiates the mechanical functioning of the 
heart, thus the atrial contraction is considered to be the starting point of the 
cardiac cycle. The different phases in the cardiac cycle are defined by shifts 
in the myocardial mechanical work rather than by the opening or closure of 
the cardiac valves. The terms pre-and post-ejection are used instead of 
isovolumic contraction and relaxation. ROI is chosen at the level of mitral 
annulus at six different locations of the LV which are: anterior septal, 
anterior, anterior lateral, inferior lateral, inferior, inferior septal, and inferior 
and accordingly the at the level of tricuspid annulus of RV free wall The six 
phases of the cardiac mechanical events in one cardiac cycle were manually 
identified as: atrial contraction, pre-ejection period (PEP), ventricular ejection 
time (ET), post-ejection period (POP), rapid filling/early diastole, and slow 
filling/diastasis (Fig 22). The software measured the duration of each phase. 
Subsequently, myocardial performance index of the left and right ventricles 
(LVMPI, RIMP) were obtained as follows PEP + POP/ET. Peak myocardial 
velocity during ventricular ejection (S), early diastolic velocity (E´) and late 
diastolic velocity (A´) were obtained from the software (Figure 19). Then ratio 
of E´/A´ was calculated. 
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Figure 22.Image of data processing in GHLab. 
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3.9 STATISTICS 
Data was analyzed using commercially available statistical software (SPSS 
version 16 and version 22, IBM Corporation, Armonk, NY, USA)). In addition, 
MATLAB was used in study III. Normal distribution of continuous data was 
tested by visual inspection of histograms assessing normality. In addition, 
normality was assessed using Shapiro-Wilks test. Normally distributed, 
continuous data are reported as means ± SD. Non-normally distributed, 
continuous variables are reported as medians and quartiles. Categorical data 
are presented as frequencies and percentages.  
Normally distributed, paired data were compared using students paired t-
test. Wilcoxon’s signed-rank test was used to compare paired data that were 
not normally distributed. Fisher exact test or Chi-square was used to 
compare proportions. Non-parametric data were analyzed using Mann-
Whitney. 
In study IV, empiric receiver operating characteristic (ROC) curve was used 
to determine the cut-off value of the BNP in predicting death and major 
adverse outcomes (MACES). The level of significance for predicting  MACE 
was determined using BNP, Clinical- and echocardiographic variables in a 
univariate regression model, in order to assess the independent association 
of variables with postoperative MACE. The variables in the univariate 
regression model that were statistically significant were entered into a multi 
regression model. Unadjusted odds ratio (OR) with 95% confidence interval 
(CI) was assessed using univariate logistic regression and adjusted OR with 
95% CI was computed using multivariate regression analysis. 
 
3.10 ETHICS 
The study was conducted in adherence to Declaration of Helsinki. Written 
informed consent was obtained from all participants in all studies. Local or 
regional Ethical committees approved the studies. 
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4 RESULTS 
Tables 1 and 2 show clinical characteristics and medical therapy of the DTI-cohort in (study 
I, II & IV). 
 
Table 1. Baseline clinical characteristics (n=46), studies (I,II & IV) 
Parameters Result 
Female/male gender [n (%)] 9 (19.6) / 37 (80.4) 
Age [years, mean (SD)] 64.3 (9.6) 
Systolic blood pressure [mmHg, mean (SD)] 148.6 (21.2) 
Diastolic blood pressure [mmHg, mean (SD)] 84.3 (10.5) 
Body mass index [Kg/m2, mean (SD)] 26.7 (3.1) 
Creatinine [µmole/L, mean (SD)] 97.0 (21.2) 
Hypertension [n (%)] 22 (47.8%) 
Hyperlipidemia [n (%)] 43 (93.5%) 
Diabetes [n (%)] 10 (21.7%) 
Smoker [n (%)] 9 (19.6%) 
Previous MI [n (%)] 20 (43.5%) 
CCS class [n (%)]   
I 5 (10.9%) 
II 29 (63.0%) 
III 11 (23.9%) 
IV 1 (2.2%) 
Coronary angiography [n (%)]   
One-vessel disease 1 (2.2) 
Two-vessel disease 7 (15.2) 
Multi vessel disease 38 (82.6) 
n (%): number of patients with percentages in parentheses; SD: Standard deviation; MI: 
myocardial infarction; CCS: Canadian Cardiovascular Society. 
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4.1 STUDY I 
Thirty six patients were included in the study. Only 6 patients (16.67%) were 
females. Previous myocardial infarction (MI) was present in 18 patients 
(50%). Angiography prior to CABG showed 3-vessel disease in the majority of 
patients (80%), .Except for Nitrates, patients were treated with same medical 
therapy following CABG as compared to before CABG. Before CABG 20 
patients (56%) were treated with Nitrates. While, only 1 patient (2.8%) was 
treated with Nitrates following CABG . 
 
4.1.1 Impact of CABG on LV function 
Ejection fraction (EF) was mildly reduced at rest before CABG and it did not 
improve when values from pre-CABG was compared to post-CABG (42 ± 8% 
vs 43.7 ± 8%, P=0.4). However, EF improved during DSE comparing values 
from pre- to post-CABG (49.2 ± 9% vs 54.2 ± 9%, P= 0.01), (Table 3). Prior to 
CABG an ischemic response was observed in the majority of patients (34 
(94.4%)) during DSE while, after CABG an ischemic response was seen only 
in 2 patients (2 (5.6%); P<0.0001). Similarly, WMSI improved significantly 
following CABG (1.40 vs 1.08, P<0.001). 
Table 2. Medical therapy before CABG and 3 months after CABG (n=46), Study (I, II & IV) 
Variable 
Before CABG                                        
n (%) 
After CABG                                   
n (%) 
P-value 
Beta-blocker  40 (87.0) 39 (86.7) 1.00 
Calcium channel inhibitor 13 (28.3) 4 (8.9) 0.039 
Long acting nitrates 30 (65.2) 1 (2.2) <0.001 
 Diuretics 9 (19.6) 8 (17.8) 1.00 
ACE-I/ARB 12 (26.1) 16 (35.6) 0.388 
 Statins 40 (87.0) 43 (95.6) 0.125 
 Digoxin 1 (2.2) 1 (2.2) 0.831 
 Insulin 5 (10.9) 4 (8.9) 1.00 
Oral glucose-lowering agents 3 (6.5) 4 (8.9) 1.00 
ASA 45 (97.8) 42 (93.3) 0.625 
n (%): number of patients with percentages in parentheses; CABG: Coronary artery bypass grafting; ACE-I: Angiotensin-
converting enzyme inhibitor; ARB: Angiotensin receptor blocker; ASA: Acetyl salicylic acid 
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Table 3. Echocardiographic measurements of the left ventricular function at rest and peak 
DSE, before and after CABG 
Echocardiographic 
parameters 
Rest                     
pre-CABG 
Rest                  
post-CABG 
DSE          
pre-CABG 
DSE               
post-CABG 
LV (ICT+IVRT) (msec) 
177.0 (36) 135.3 (18)***   150.0 (31) 107.6 (22)*** 
LV -ET (msec) 
341.0 (31) 307.9 (30)*  194.2 (35) 197.7 (29) 
LV-MPI 
0.61 (0.13) 0.45 (0.08)***    0.78 (16) 0.56 (0.1)*** 
EF (%) 
42.7 (8) 43.7 (8) 49.2 (9) 54.2 (99)** 
LV S (cm/sec) 
6.4 (1.4) 6.4 (1.3) 8.9 (2.3) 9.0 (2.8) 
LV E´ (cm/sec) 
7.5 (2) 7.9 (1.8) 8.3 (1.9) 9.7 (3.0)* 
LV A´(cm/sec) 
8.4 (2) 7.7 (2.6) 11.6 (3.2) 10.7 (4.6) 
Mitral E (m/s) 
0.66 (0.17) 0.69 (0.19) 0.61 (0.21) 0.78 (0.20)** 
Mitral A (m/s) 
0.68 (0.19) 0.58 (0.20)**   0.83 (0.20) 0.85 (0.23) 
Mitral E/A ratio 
1.1 (0.51) 1.37 (0.71)**   0.74 (0.32) 0.94 (0.35)** 
LV E/E' ratio 
9.3 (3.1) 9.1 (2.8) 7.6 (2.6) 8.5 (2.4) 
Heart rate (beats/min) 
58 (10) 63 (10)* *  127 (14) 130 (18) 
Data is represented as mean (SD). CABG: Coronary artery bypass grafting; DSE: Dobutamine stress echocardiography; ICT: 
Isovolumic contraction time, IVRT: isovolumic relaxation time; ET: Ejection time; MPI: myocardial performance index; EF: 
ejection fraction; LV: Left ventricular; S: peak annular longitudinal tissue velocity; E’ (early) and A’ (late): peak annular 
longitudinal tissue velocity; E: peak early inflow velocity; A: peak late inflow velocity. 
Paired t-test: pre-CABG vs post-CABG. 
  
*    P < 0.05.         
**. P < 0.01.         
*** P < 0.001.         
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Global LV function assessed by LVMPI improved at rest when comparing 
values from pre-CABG to post CABG (0.60 ± 0.13 vs 0.45 ± 0.08, P<0.001), 
(Table 3). Accordingly, compared to pre- CABG LVMPI improved at peak DSE 
after CABG (0.78 ± 0.16 vs 0.56 ± 0.1, P<0.001), (Fig. 23). Accordingly, the 
improvement was consistent when LVMPI was adjusted for heart rate 
(P<0.001). 
 
 
Figure 23. Alterations in LV-MPI from rest to peak DSE before and after CABG. LV: left ventricular, 
MPI: Myocardial performance index; CABG: Coronary artery bypass grafting; DSE dobutamine 
stress echocardiography. 
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4.2 STUDY II 
Forty-two patients were included in the study. Mean age was (64 ± 9) years; 
8 (19.0%) patients were female. Nineteen (45.2%) patients had hypertension, 
9 (21.4%) had diabetes and 18 (42.9%) had a history of previous MI. Thirty-
five patients (83.3%) had 3-vessel disease, whereas 37 (88.09%) had 
significant right coronary artery (RCA) stenosis. Conventional 
cardiopulmonary bypass was used in all patients undergoing CABG. 
Following CABG, open grafts were seen in 34 (80.9%) patients at follow-up 
angiography 3 months after CABG. 
 
4.2.1 Impact of CABG on right ventricular function 
Prior to CABG, RV systolic function as assessed by TAPSE (23.9 ± 4.5) and 
RVS (11.9 ± 2.4) was normal. Accordingly, global RV performance quantified 
by RIMP (0.45 ± 0.11) was also normal. Compared to pre-CABG, TAPSE (14.6 
± 3.7, P<0.001) and RVS (8.5 ± 1.9) deteriorated following CABG. On the other 
hand, RIMP (0.38 ± 0.08) improved after CABG (Fig. 24). The results of 
echocardiographic measurements of RV function at rest and peak DSE are 
shown in Tables 4 and 5. 
 
 
Figure 24. Alterations in RIMP from rest to peak DSE before and after CABG. RIMP: right ventricular 
index of myocardial performance; CABG: Coronary artery bypass grafting; DSE dobutamine stress 
echocardiography  
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Table 4. Echocardiographic assessment of right ventricular size and function at rest 
before and after CABG (n=42) 
Parameter 
Rest                                         
Pre-CABG 
Rest                    
Post-CABG 
P-value 
RIMP 0.45 ± 0.11 0.38 ± 0.08 0.013 
RV systolic function   
 
TAPSE (mm) 23.9 ± 4.5 14.6 ± 3.6 <0.001 
RV peak systolic velocity ( S´, cm/s) 11.9 ± 2.4 8.5 ± 1.9 <0.001 
RV diastolic function    
Tricuspid peak E-wave velocity  (E, m/s) 0.43 ± 0.09 0.46 ± 0.13 0.18 
Tricuspid peak A-wave velocity (A, m/s) 0.38 ± 0.07 0.5 ± 0.76 0.33 
Tricuspid E/A ratio 1.2 ± 0.33 1.2 ± 0.38 0.69 
RV early diastolic velocity (e´, cm/s) 11.4 ± 3.01 8.0 ± 2.80 <0.001 
RV late diastolic velocity (a´, cm/s) 13.7 ± 3.50 8.4 ± 2.87 <0.001 
RV E/e' ratio 4.1 ± 1.32 6.3 ± 2.69 <0.001 
Cardiac time intervals (PW-DTI):     
RV IVCT (ms)  72.1 ± 17.17 63.5 ± 13.52 0.005 
RV ET (ms) 307 ± 36.65 306 ± 35.25 0.84 
RV IVRT (ms) 67 ± 25.29 57 ± 25.23 0.038 
Heart rate (beats/min) 58 ± 9 61±14 <0.05 
Data is presented as mean ± SD; CABG: coronary artery bypass grafting; RIMP: right ventricular index of myocardial 
performance; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; S: peak annular longitudinal tissue 
velocity; E: peak early inflow velocity; A: peak late inflow velocity; E’ (early) and A’ (late): peak annular longitudinal 
tissue velocity; IVCT: Isovolumic contraction time; ET: Ejection time; IVRT: Isovolumic relaxation time.  
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Table 5. Echocardiographic assessment of right ventricular size and function at peak 
DSE before and after CABG (n=42) 
Parameter 
 Peak DSE                   
Pre-CABG 
peak DSE                  
Post-CABG 
P-value 
RIMP 0.75 ± 0.23 0.49 ± 0.14 <0.001 
RV systolic function   
 
TAPSE (mm) 20.9 ± 4.2 11.9 ± 3.6 <0.001 
RV S´(cm/s) 15.6 ± 4.3 10.5 ± 3.2 <0.001 
RV diastolic function    
Tricuspid E (m/s) 0.49 ± 0.11 0.67 ± 0.12 <0.001 
Tricuspid (A, m/s) 0.59 ± 0.19 0.63 ± 0.22 0.32 
Tricuspid E/A ratio 0.88 ± 0.23 1.1 ± 0.29 0.001 
RV e´ (cm/s) 13.8 ± 5.10 10.6 ± 4.10 <0.001 
RV (a´, cm/s) 19.4 ± 5.05 13.7 ± 3.53 <0.001 
RV E/e' ratio 4.2 ± 1.81 7.5 ± 2.81 0.001 
Cardiac time intervals (PW-DTI):     
RV IVCT (ms) 62 ± 17.75 47 ± 16.56) 0.020 
RV ET (ms) 196 ± 32.12 205 ± 39.05 0.15 
RV IVRT (ms) 82 ± 34.01 51 ± 21.49 0.004 
Heart rate (beats/min) 126 ± 14 130 ± 18 0.952 
Data is presented as mean ± SD; DSE: dobutamin stress echocardiography; CABG: coronary artery bypass grafting; RIMP: 
right ventricular index of myocardial performance; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; 
S: peak annular longitudinal tissue velocity; E: peak early inflow velocity; A: peak late inflow velocity; E’ (early) and A’ 
(late): peak annular longitudinal tissue velocity; IVCT: Isovolumic contraction time; ET: Ejection time; IVRT: Isovolumic 
relaxation time.  
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4.3 STUDY III 
Forty patients were enrolled in the study. Twenty patients were randomized 
to MIAVR and 20 patients to AVR. One patient who was randomized to 
MIAVR, crossed over to AVR due to difficulties in cardioplegia during surgery. 
Following surgery, 2 (10.5%) patients in the AVR group died. One patient died 
on day 2, post surgery due to pancreatitis and multi organ dysfunction and 
one patient died on day 4 due to undiagnosed liver cirrhosis. Finally, 19 
patients remained in each group and analyzed. The patients were analyzed 
as treated. Mean age was marginally but not significantly higher in the AVR 
as compared to MIAVR (70.8 ± 8.0 vs 67.3 ± 9.0, P = 0.22). At baseline, there 
were not any significant differences in comorbidities (i.e. Hypertension; 
Diabetes; Previous stroke; previous coronary artery intervention and renal 
failure) between the groups (Table 6). Accordingly, baseline medication was 
similar between the 2 groups both before and after aortic valve replacement 
surgery. However, the cardiopulmonary bypass time was significantly longer 
in the MIAVR arm (113.4 ± 36.0 vs 88.7 ± 28.2, P = 0.04), (Table 7). 
 
Table 6. Baseline Clinical Characteristics (n=38) 
Patient characteristics Total (n=38) 
AVR 
(n=19) 
MIAVR (n=19) 
P-
value 
Female gender 15 (39.5%) 8 (42.1%) 7 (38.8%) 0.74 
Age (years), mean (SD) 70 (9) 70.8 (8) 67.3 (9) 0.22 
Body mass index (kg/m²), mean (SD) 27.9 (5.1) 28.0 (5.9) 27.8 (4.4) 0.55 
Systolic blood pressure (mmHg), mean (SD) 133 (16) 132 (13) 134(20) 0.70 
Diastolic blood pressure (mmHg), mean (SD) 73 (9) 72 (10) 73 (8) 0.89 
Hypertension 25 (65.8%) 13(68.4%) 12 (63.2%) 0.73 
Diabetes mellitus 9 (23.7%) 5 (26.3%) 4 (21.1%) 0.70 
Insulin-dependent  5 (13.1%) 1 (5.3%) 4 (21.0%) 0.08 
Hyperlipideamia 14 (36.8%) 6 (31.6%) 8 (42.1%) 0.50 
Chronic pulmonary disease 2 (5.3%) 0 2 (10.5%) 0.08 
Previous stroke 2 (5.3%) 2 (10.5%) 0 0.15 
Previous PCI 1 (2.6%) 0 1 (5.3%) 0.31 
Renal failure 2 (5.3%) 0 2 (10.5%) 0.15 
ECG 
    
LBBB/RBBB 4 (10.5%) 3 (15.8%) 1 (5.3%) 0.15 
Values are presented as n (%) unless otherwise noted. PCI: percutaneous coronary intervention. LBBB: left bundle branch block; 
RBBB: right bundle branch block. 
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4.3.1 Impact of AVR and MIAVR on right heart size and function 
The RV 2D size remained unchanged following both AVR and MIAVR. On the 
other hand compared to pre-surgery values, RV systolic function was 
deteriorated following both AVR and MIAVR. Compared to pre-surgery, 
TAPSE decreased following AVR (26.1 ± 4.6 vs 15.6 ± 3.3; P<0.0001) as well 
as following MIAVR (24.8 ± 3.7 vs 19.2 ± 3.8; P = 0.001). Although, the 
magnitude of post-surgical reduction in TAPSE was significantly higher post-
AVR (39.9%) as compared to post-MIAVR (21.6%, P = 0.007 (Fig. 25). 
Accordingly, RVS declined following surgery as compared to pre-surgery both 
following AVR (9.3 ± 2.1 vs 5.9 ± 1.5; P<0.01) and following MIAVR (10.1 ± 
2.9 vs 8.2 ± 1.4, P<0.01). Similarly the magnitude of post-surgical reduction 
in RVS was significantly higher post-AVR (36.6%) as compared to MIAVR 
(18.8%; P<0.001).  
Table 7: Perioperative data (n=38) 
Parameter AVR (n=19) MIAVR (n=19) P-value Total (n=38) 
Cardio pulmonary bypass time (min) 88.7 ± 28.2 113.4 ± 36 0.040 102 ± 35 
Aorta cross clamp time (min) 70.7 ± 22 82.9 ± 26.9 0.72 77 ± 25 
Valve type     
Biological prosthesis 14 (73.7%) 14 (73.7%) 0.72 29 (72%) 
Mechanical prosthesis 5 (26.3%) 5 (26.3.6%) 0.72 10 (25%) 
Sutureless 0 7 (36.8%) 0.003 7 (18.4%) 
valve size (mm) 23 ± 1.3 23 ± 1.7 0.070 23 ± 1.6 
     
De novo pacemaker 1 (5.3%) 0 0.40 1 (2.6%) 
PEX day 1 7 (36.8%) 10 (52.6%) 0.48 17 (44.7%) 
PEX day 4 15 (78.9%) 16 (84.2%) 0.72 31 (81.6%) 
Tamponade 1 (5.2%) 2 (10.5%) 0.62 3 (7.9%) 
30 days Mortality 2 (10%) 0 0.22 2 (5.2%) 
Data is expressed as mean ± SD or number (%). AVR: aortic valve replacement; MIAVR: minimally invasive aortic valve 
replacement; PEX: pericardial exudate. 
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Figure 25. Changes in TAPSE following aortic valve replacement surgery. TAPSE: tricuspid 
annular systolic excursion, AVR: aortic valve replacement surgery; MIAVR: minimal invasive 
aortic valve replacement surgery. 
 
Prior to surgery, RVFAC was normal in the AVR-group (54.3 ± 7.7%) as well 
as in the MIAVR-group (55.5 ± 6.4%). Following surgery, a significant 
reduction in RVFAC was observed in both AVR (47.7 ± 11.2%; P<0.01) and 
MIAVR (51 ± 8.5%; P<0.05). However, in both groups RV FAC still remained 
within the normal range following surgery. Prior to surgery, no significant 
difference in RV performance as quantified by RIMP was observed. After 
surgery, RIMP was equally deteriorated (prolonged) in both groups (AVR 
(33.3%) vs MIAVR (30.8%); P = 0.25). Before surgery, RV-LS and RV-LSR were 
within normal range and without any significant differences between the 
groups. After surgery, RV-LS was equally deteriorated in both groups. On 
comparing pre- to post surgery values, RV-LSR was deteriorated following 
AVR (-1.7 ± 0.3 1/s vs -1.4 ± 0.3; P<0.01), while it was preserved following 
MIAVR (-1.5 ± 0.5 vs -1.5 ± 0.4 1/s; P = 0.84), (Table 8). Echocardiographic 
characteristics of LV size and function before and after aortic valve 
replacement surgery in the two surgical groups is displayed in Table 9.  
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Table 8. Pre- and postoperative echocardiographic assessment of right heart size and function in the two 
surgical groups 
 Before aortic valve 
surgery 
After aortic valve 
surgery 
P-value 
Echocardiographic 
Parameter 
AVR MIAVR AVR MIAVR 
Between 
the groups 
pre† 
Between 
the groups 
post† 
TAPSE (mm) 26.26 ± 4.5 24.5 ± 3.6 15.8 ± 3.2*** 
19.2 ± 
3.8*** 
0.20 0.005 
RVS (cm/s) 9.3 ± 2.1 10.1 ± 2.9 5.9 ± 1.5** 8.2 ± 1.4** 0.39 < 0.001 
RVE´ (cm/s) 8.4 ± 2.9 7.1 ± 2.1 4.7 ± 2.9** 4.7 ± 2*** 0.14 0.99 
RVA´ (cm/s) 12.2 ± 3.5 12.2 ± 2.9 4.9 ± 1.9** 9 ± 3.2*** 0.97 < 0.01 
RV E´/A´ 0.84 ± 0.61 0.6 ± 0.21 1.1 ± 0.9 0.55 ± 0.3 0.17 0.04 
FAC (%) 54.3 ± 7.7 55.5 ± 6.4 
47.7 ± 
11.2** 
51 ± 8.5* 0.70 0.56 
RV longitudinal strain (%)  -27.4 ± 3  -26.5 ± 5.3 
 -18.8 ± 
4.7*** 
 -20.7 ± 
4.5** 
0.56 0.25 
RV strain rate (1/s)  -1.7 ± 0.3  -1.6 ± 0.3  -1.4 ± 0.3**  -1.5 ± 0.4 0.65 0.53 
RIMP 0.75 ± 0.2 0.68 ± 0.16 1 ± 0.4** 
0.89 ± 
0.2** 
0.26 0.25 
PEP (ms) 123.1 ± 62 104 ± 29 136 ± 29 129 ± 41* 0.25 0.69 
ET (ms) 300.5 ± 40 308.7 ± 37 256.2 ± 49* 267.4 ± 54* 0.54 0.56 
POP (ms) 100 ± 27 103.7 ± 25 116 ± 30 100 ± 35 0.74 0.19 
RVOT prox (mm) 30.06 ± 3.2 30.2 ± 3.9 29.2 ± 3.9 29.2  ± 4.2 0.84 0.79 
RVD1 (mm) 31.05± 4 32.1± 4.4 32.3 ± 4.7* 33.5 ± 3.4* 0.75 0.39 
RA volume (ml) 40.3 ± 16.7 42.6 ± 16.1 45.3± 20.8* 45.1 ± 14.7* 0.16 0.40 
TR Vmax (m/s) 2.7 ± 0.4 2.5 ± 0.87 1.9 ± 1.1* 1.7 ± 1.1 0.54 0.67 
SPAP (mmHg) 37.5 ± 9.1 31.7 ± 13.7 27.9 ± 6.7* 22.8 ± 13.6 0.76 0.62 
HR (min¯¹) 69.6 ± 12 63.4 ± 9.1 72.5 ± 13.7* 71.2 ± 13* 0.22 0.75 
RV: right ventricle; AVR: aortic valve replacement; MIAVR: minimally invasive aortic valve replacement; TAPSE: tricuspid annulus systolic 
excursion; S: peak systolic myocardial velocity; E´: early diastolic myocardial velocity; A´: late diastolic myocardial velocity; FAC: fractional area 
change; RIMP: right ventricular index of myocardial performance; PEP: pre ejection period; ET: ejection time; POP: post ejection time; RVOT prox: 
proximal RV outflow diameter; RVD1: RV basal linear dimension; RA: right atrial; TR: tricuspid regurgitation; SPAP: systolic pulmonary artery 
pressure; HR: heart rate. 
Paired t test vs baseline:             
*  p < 0.05.             
** p < 0.01.             
*** p < 0.001.             
† Independent samples t-test to compare degree of changes between AVR and following MIAVR. 
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Table 9. Pre- and postoperative echocardiographic assessment of left heart size and function in the two 
surgical groups. 
 Before aortic valve surgery Post aortic valve surgery P-value 
Parameter AVR MIAVR AVR MIAVR 
Between the 
groups pre†  
Between the 
groups post†  
LVEDD (mm) 44.8 ± 5.1 46.3 ± 5.3 43.65 ± 4.9* 47.1 ± 5.6 0.67 0.03 
LVESD (mm) 26.9 ± 6.2 28.7 ±  6.9 26.7 ± 5.1 30.6 ± 6.9 0.40 0.03 
LVEDV (ml) 85.6 ± 19.9 102 ± 30 82 ± 17.2 100.5 ± 29.7 0.14 0.03 
LVESV (ml) 34.9 ± 10.4 42.3  ±  13.3 36.1 ± 10.4 45.5 ± 14.9 0.11 0.04 
LVEF (%) 60.2 ± 5.7 57.8 ± 6.3 56.5 ± 5.4** 54.6 ± 6.5 0.33 0.37 
LVGLS (%)  -16.5 ± 8.1 
 -17.4  ±  2.1 
  
 -15.7  ± 2.7  -16.9 ± 2.1 0.64 0.21 
LVMPI 0.81 ± 0.26 0.75 ± 0.16 0.91 ± 0.18 0.89 ± 0.15** 0.37 0.63 
Mitral E (m/s)  0.81 ± 0.31 0.8 ± 0.27 0.84 ± 0.23 0.89 ± 0.29 0.72 0.71 
Mitral A (m/s) 0.98 ± 0.37 0.81 ± 0.36 0.89 ± 0.28* 0.79 ± 0.26 0.14 0.61 
Mitral E/A 0.84 ± 0.22 1.2 ± 0.86 0.98 ± 0.27 1.2 ± 0.43 0.14 0.46 
Dec T (ms) 228.8 ± 61 201.1  ±  58.4 200 ± 50 203.7 ± 49.7 0.30 0.59 
LA volume (ml) 83.2 ± 23.3 79.6  ±  20.5 75.2 ± 22.1 79.8 ± 23.7 0.53 0.58 
HR (min¯¹) 69.6 ± 12 63.4 ± 9.1 72.5 ± 13.7* 71.2 ± 13* 0.22 0.75 
LV: left ventricle; EDD: end diastolic diameter, ESD: end systolic diameter; EDV: end diastolic volume; ESV: end systolic volume; EF: ejection fraction; GLS: 
global longitudinal strain; MPI: myocardial performance index; E: early diastolic flow velocity; A: late diastolic flow velocity; Dec T: deceleration time; LA: 
left atrium; HR: heart rate. 
Paired t test vs 
baseline:             
*    p < 0.05.             
**  p < 0.01.             
*** p < 0.001.             
† Independent samples t-test to compare degree of changes between AVR and MIAVR. 
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4.4 STUDY IV 
4.4.1 TOTAL COHORT 
Eighty-eight patients were included in the study of which, 13 (14.8%) were 
females. Mean age was (63.8 ± 9.0). The number of patients with diabetes 
was 21 (23.9%); hypertension 36 (40.9%); hyperlipidemia 80 (90.9%), 
previous MI 48 (54.5%). Eighteen (20.5%) patients were smokers (Table 10). 
During the follow up period of 5 years after CABG, major adverse 
cardiovascular events (MACE) was observed in 17 (19.3%) patients: 6 (6.8%) 
patients died; 8 (9.1%) patients were treated with PCI of which 5 patients 
suffered from MI; and 3 patients were treated for congestive heart failure 
(CHF). 
On comparing to patients without MACEs, patients experiencing MACEs 
were significantly older (62.7 ± 8.7 vs 67.3 ± 9.2; P = 0.028) and had 
moderately impaired renal function (creatinine clearance: 68.2 ± 17.6 vs 
84.0 ± 12.0 ml/min; P = 0.006). In addition, larger proportion of patients 
experiencing MACEs had hypertension as compared to those without 
MACEs (36 (40.9%) vs 23 (34.3%); P = 0.025). 
On comparing medication between the 2 groups, before CABG a higher 
proportion of patients who did not experience MACEs were treated with 
Beta-blockers (70.6% vs 91.0 %; P = 0.009). However, after CABG there was 
no significant difference between the 2 groups’ beta blocker treatment. On 
the other hand, lower proportion of patients experiencing MACEs were 
treated with statins as compared to those without any events (76.5% vs 
95.8%; P = 0.008).  
Seventy four (84.1%) patients underwent follow-up angiography 3 months 
after CABG . Twenty-two (29.7%) patients had one or more occluded grafts. 
There was no significant difference in BNP values comparing patients with- 
or without graft-occlusion (524 [quartile 1: 208, quartile 3: 1099].vs 272 
[1:160, 556]; P=0.267). 
 
4.4.2 Subpopulation of patients with DTI 
Forty patients were analyzed in the subpopulation. A total of 10 (25%) 
patients experienced MACEs during the 5 years of follow-up: 4 (10.0%) 
patients died, 3 (7.5%) patients were treated for AMI, 1 (2.5%) patient was 
treated for heart failure and 5 (12.5%) patients underwent PCI. There was no 
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significant difference in co-morbidities or medications between those who 
experienced MACEs and those who did not (Table 2). 
 
Table 10. Baseline clinical characteristics in total cohort (n=88) 
 
  
Patient characteristics 
Patients without                                        
MACEs (n=71) 
Patients with                                  
MACEs (n=17) 
P Value 
Male/Female,  n(%) 
57 (80.28)/10 
(14.08) 
18 (85.71%)/3 
(14.29%) 
0.9 
Age (years), (SD) 62.75 (8.67) 67.33 (9.24) 0.0 
Body mass Index (kg/m2) 35.29 (2.94) 32.99 (2.89) 0.7 
Diabetes, n(%) 18 (26.86%) 3 (14.29%) 0.2 
Hypertension,  n(%) 23 (34.32%) 13 (61.90%) 0.0 
Hyperlipidemia,  n(%) 62 (92.54%) 18 (85.71%) 0.3 
Creatinine Clearance (ml/min), (SD) 84.02 (21.01) 68.17 (17.58) 0.0 
Previous myocardial infarction,  n(%) 34 (57.75) 14 (66.67%) 0.2 
Smoker,  n(%) 15 (22.39%) 3 (14.29%) 0.4 
Ex-smoker (> 3 months),  n(%) 24 (35.82%) 9 (42.86%) 0.6 
Systolic Blood pressure (mmHg), (SD) 142.05 (18.75) 149.05 (15.86) 0.1 
Diastolic Blood Pressure (mmHg), 
(SD) 
81.44 (10.59) 83.33 (8.71) 0.5 
Data is presented as n (%): number of patients with percentages in parentheses or mean (SD); SD: Standard 
deviation. 
 
4.4.3 BNP and echocardiographic measurements in overall population 
Generally compared with baseline, plasma BNP concentration (median: 311 
[quartile 1: 147, quartile 3: 571] pg/ml), increased significantly after CABG 
(387 [182.8, 779] pg/ml; P = 0.038) and a significant correlation between pre- 
and post-CABG BNP concentrations was observed (r = 0.57: P<0.0001). On 
comparing patients with- and without MACEs, BNP levels were significantly 
higher in patients with MACEs, both prior to CABG (464 [289.5, 632.5] pg/ml 
vs. 268 [143, 555] pg/ml: P = 0.027) and post-CABG (1096 [754, 1684.5] vs. 
299 [170, 558] pg/ml; P<0.0001), (Fig. 26). Accordingly, among the patients 
experiencing MACEs, BNP levels increased significantly post-CABG as 
compared to baseline (464 [289.5, 632.5] pg/ml vs. 1096 [754 vs. 1684.5] 
pg/ml; P = 0.015), (Table 11). 
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Table 11. BNP and echocardiographic measurements in patients with and without events in total 
cohort,  before and after CABG 
Parameter 
No Event pre                              
(n=71) 
 Event pre                                
(n=17) 
P 
Value 
No Event post                              
(n=71) 
Event post                                 
(n=17) 
P Value 
BNP (ng/L) 477.14 ± 601.26                        
268(143, 555) 
702.82 ± 879.83                      
464 (289.5, 632.5) 
0.027 442.04 ± 459.91                   
299 (170, 558) 
1253.41 ± 1080.77                 
1096 (754, 1684.5) 
<0.0001 
EF (%) 43.01 ± 8.1                             
43 (37, 48.25) 
41.93 ± 7.48                                 
40 (38, 48) 
0.433 43.88 ± 7.92                
43 (40, 49) 
42.25 ± 8.83                      
43 (36.75, 46.5) 
0.44 
Mitral E/A  1.04 ± 0.47                                              
0.89 (0.8, 1.2) 
0.89 ± 0.29                             
0.75 (0.71, 1.17)                           
0.124 1.20 ± 0.56                                              
1.0 (0.83, 1.5) 
1.3 ± 0.77                   
0.94 (0.79, 2.05)                  
0.942 
Mitral E/E' 9.61 ± 6.59                                                       
8.01 (6.77, 10.5) 
9.92 ± 3.89                           
8.3 (6.67, 14.29)            
0.561 8.04 ± 2.45                                                   
7.91 (6.25, 9.75) 
9.74 ± 3.88            
9.41 (6.75, 11.99)  
0.067 
Tri. E/A 1.19 ± 0.31                                                   
1.15 (1, 1.33) 
1.15 ± 0.26                                                
1.20 (1, 1.29)        
0.655 1.27 ± 0.40                                                   
1.25 (1.0, 1.40) 
1.35 ± 0.34                  
1.33 (1.25, 1.43) 
0.870 
Tri. E/E' 4.15 ± 1.35                                               
3.75 (3.08, 5.) 
3.68 ± 1.13                            
3.57 (2.85, 4.) 
0.367 6.32 ± 2.69                                                  
6.30 (4.35, 7.32) 
5.65 ± 1.45                   
5.71 (4.55, 6.46)   
0.401
HR 
(beat/min) 
61.86 ± 12.94                             
59 (51, 63) 
63.31 ± 12.34                             
62 (52, 80) 
0.619 67.30 ± 15.03                        
64 (58.5, 72) 
65.73 ± 12.29                       
63 (56, 76) 
0.447 
Data is presented as mean ± SD and median (quartile 1, quartile 3).                                                                                                                                                                                        
BNP: B-type natriuretic peptide; EF: Ejection fraction; E: early diastolic flow velocity; E`: early diastolic tissue velocity, Tri: 
Tricuspid; HR: Heart rate; CABG: coronary, artery bypass grafting.                                                                                                                                                                                                                                                                                                                                                         
Pre: before CABG; post: after CABG. 
 
 
Figure 26. BNP levels in patients with and without MACEs in total cohort, assessed before and after 
CABG. BNP: Brain natriuretic peptide, CABG: Coronary artery bypass grafting. 
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4.4.4 BNP and echocardiographic measurements in subpopulation  
In the subpopulation, a total of 40 patients were analyzed. The alteration in 
BNP level in the subpopulation after CABG was similar to the total 
population. Compared with baseline values plasma BNP concentration 
(median: 272 [quartile 1: 109.5, quartile 3: 476.8] pg/ml), increased 
significantly after CABG (386.5 [173, 1091] pg/ml; P = 0.002). Analyzing the 
BNP levels among the patients in the subpopulation with MACEs compared 
to those without, a significantly higher level of BNP was measured pre-CABG 
(472 [300.8, 604.8] pg/ml vs. 219.5 [98.0, 380.3] pg/ml: P = 0.024). 
Accordingly, patients with MACEs had significantly higher levels of BNP post-
CABG as compared to baseline (1160 [1009.8, 1637.8] pg/ml vs. 246 [155.8 
vs. 460.8] pg/ml; P = 0.001), (Table 12). 
 
Table 12. Comparison of BNP and echocardiographic measurements in patients with and without 
events in the subpopulation of patients with DTI-measurements , before and after CABG 
Parameter 
No Event pre                              
(n=30) 
Event pre                                    
(n=10) 
P
Value 
No Event post                              
(n=30) 
Event post                                    
(n=10) 
P
Value 
BNP 
(pg/ml) 
356.2 ± 480.8                        
219.5 (98, 380.25) 
510.9 ± 332.5                       
472(300.8, 604.8) 
0.024 
435.5 ± 565.4                     
246 (155.8, 
460.8) 
1180.3 ± 506.5                    
1160 (1009.8, 
1637.8) 
0.001 
LVMPI 0.60 ± 0.11                           
0.59 (0.53, 0.68) 
0.61 ± 0.14                           
0.6 (0.54, 0.65) 
0.890 0.43 ± 0.08                           
0.44 (0.38, 0.48) 
0.49 ± 0.07                           
0.49 (0.40, 0.54) 
0.891 
RIMP 0.44 ± 0.11                           
0.44 (0.38, 0.53) 
0.44 ± 0.12                           
0.49 (0.37, 0.51) 
0.883 0.39 ± 0.11                           
0.38 (0.30, 0.45) 
0.41 ± 0.08                           
0.39 (0.37, 0.43) 
0.649 
EF (%) 42.51 ± 7.66                             
42 (38, 47) 
44.06 ± 9.2                                  
44 (35.5, 50.5) 
0.632 43.90 ± 8.29                              
43 (39.25, 49) 
42.29 ± 7.14                               
43 (40.5, 44.5) 
0.590 
Mitral E/A  1.05 ± 0.54                                              
0.88 (0.79, 1.22) 
1 ± 0.33                          
1 (0.69, 1.33)                           
0.973 1.30 ± 0.71                                              
1.18 (0.79, 1.61) 
1.46 ± 0.78                        
1.16 (0.86, 2.41)                  
0.660 
Mitral E/E'  9 ± 2.79                                                       
9.33 (6.76, 10.89) 
10.29 ± 4.25                           
9.04 (6.1714.51)            
0.566 8.57 ± 2.59                                                   
8.42 (6.4, 10.39) 
9.42 ± 2.72                          
9.64 (6.59, 11.34)  
0.334 
Tri. E/A  1.24 ± 0.33                                                   
1.25 (1, 1.33) 
1.11 ± 0.28                                              
1.13 (0.90, 1.24)        
0.240 1.22 ± 0.39                                                   
1.25 (1, 1.33) 
1.2 ± 0.22                    
1.25 (1, 1.33) 
0.775 
Tri. E/E'  4.22 ± 1.31                                                
4 (3.12, 5.45) 
3.33 ± 0.63                       
3.57 (2.85, 3.70) 
0.136 6.45 ± 3                                                   
6.51 (4.29, 7.89) 
5.74 ± 1.56                         
5.83 (4.55, 6.69)   
0.639 
HR 
(beat/min) 
58.64 ± 8.16                             
58.5 (51.25, 66) 
61.56 ± 10.96                              
60 (52.5, 70) 
0.946 64.92 ± 12.29                        
65 (60, 69) 
59.56 ± 8.53                              
66 (53.75, 75.25) 
0.305 
Data is presented as mean ± SD and median (quartile 1, quartile 3).                                                                                                                                                                                        
BNP: B-type natriuretic peptide; EF: Ejection fraction; E: early diastolic flow velocity; E`: early diastolic tissue velocity; Tri: 
Tricuspid; HR: Heart rate; CABG: coronary, artery bypass grafting.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Pre: before CABG; post: after CABG.  
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Figure 27. Correlation between Ln BNP –LVEF and Ln BNP-Mitral E/A, before CABG: BNP: brain 
natriuretic peptide, EF: Ejection fraction; E: Early diastolic flow velocity; A: Late diastolic flow velocity; 
CABG: Coronary artery bypass grafting. 
 
A significant, negative correlation between preoperative BNP and 
preoperative EF was revealed (r = -0.34; P = 0.036), (Fig. 27). A significant, 
positive correlation between preoperative BNP and preoperative LV-MPI (r = 
0.531; P<0.001); and preoperative BNP and preoperative RIMP (r = 0.335; P 
= 0.032) was observed (Fig.28). However, no significant correlation between 
postoperative BNP and postoperative LVMPI, postoperative RIMP and 
postoperative EF respectively could be revealed.  
 
 
  
Figure 28. Correlation between Ln BNP –LVMPI and Ln BNP-RIMP, before CABG: BNP: brain natriuretic 
peptide, LVMPI: left ventricular myocardial performance index; RIMP: Right ventricular index of 
myocardial performance; CABG: Coronary artery bypass grafting 
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4.4.5 Cut-off values of postoperative BNP for detection of events 
Using ROC-curve cut-off level for postoperative BNP was assessed (Fig 29). A 
cut-off level of 602-761 pg/ml was considered optimal based on a sensitivity 
of 80.3%-76.5% and a specificity of 80.3%-87.3% for predicting MACEs 5 
year after CABG. The accuracy of postoperative BNP in predicting MACEs 
was 84.1%. 
Among clinical and echocardiographic variables that were analyzed in a 
univariate regression model postoperative BNP (P = 0.001), preoperative BMI 
(P = 0.01), pre- and postoperative creatinine clearance (P = 0.01 and P = 0.01), 
postoperative statins (P = 0.02) and preoperative beta-blockers (P = 0.02) were 
all significantly associated with the incident of MACEs at follow-up. Further 
analysis of the above variables in a multivariate logistic regression model 
revealed that postoperative BNP (P = 0.003) and preoperative BMI (P = 0.025) 
were independent predictors of MACEs. 
 
 
Figure 29. ROC-curve displaying sensitivity and specificity of postoperative BNP in detection of MACES. 
AUC: Area under the curve; CI: Confidence interval; BNP: Brain natriuretic peptide; MACES: Major 
adverse cardiovascular events. 
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5 GENERAL DISCUSSION 
Our studies reveal that despite advances in echocardiographic technology, 
controversies still remain in echocardiographic evaluation of cardiac function 
following open heart surgery. The reason is complex and multifactorial. 
However, one of the main reasons may be altered cardiac motion due to 
altered geometry and loss of pericardial constraint following opening of the 
pericardium in open heart surgery (79, 80). A number of surrogate 
parameters of RV function are one-dimensional measurements and 
influenced by cardiac translational motion resulting in an underestimation 
of RV function following heart surgery (81). Further, several 
echocardiographic modalities are angel-dependent, thus changes in cardiac 
geometric location in the chest may influence their results. The key to 
overcoming these shortcomings is to include several modalities for 
assessment of cardiac function and not rely on a sole metric. This is 
especially important in determining RV function following open heart 
surgery. It is recognized that RV movement along its longitudinal axis as 
assessed by RVS and TAPSE declines after open heart surgery (79, 82). 
However, the interpretation of these findings has been extremely divergent. 
While some studies have reported deterioration in global RV function amid 
reduced longitudinal RV movement (83), other studies using other modalities 
for assessment of RV function have reported preserved global RV function 
despite a post-surgical reduction in RV longitudinal function (84). In study 
II, our results confirm previous findings of reduction in RV longitudinal 
function following CABG (83), (85). However, we observed an improvement in 
global RV performance as assessed by RIMP both at rest and during DSE. 
Concomitantly, we observed improvements in patients’ clinical parameters 
following CABG. Consistent with previous studies (86), in our study the 
prevalence of angina dropped dramatically and the use of anti-angina 
medication reduced significantly (87). Accordingly, follow-up angiography 
demonstrated patent grafts to RCA, CX and other coronary arteries in the 
majority of patients. In addition, following CABG, exercise capacity improved 
significantly in the majority of the patients and the reason for ending the 
bicycle exercise test was fatigue, not angina. In conclusion, the cohorts’ 
clinical parameters improved significantly following CABG, while 
concurrently the RV longitudinal function diminished. Previously, it has been 
demonstrated that RV function is one of the major determinants of exercise 
capacity (88). The paradox of improved exercise capacity and reduced global 
RV performance doesn’t fit together. Rather, in this clinical setting, the 
improvement in global RV performance sounds more reasonable. 
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Accordingly, in study III, a reduction in longitudinal RV function following 
both AVR and MIAVR was observed. However, the magnitude of the reduction 
in longitudinal RV function was significantly higher following full sternotomy 
AVR. The results suggest that the accurate assessment of RV longitudinal 
motion using  conventional TAPSE and RVS is dependent upon the intact 
myocardium (80). Even smaller openings of the myocardium may result in 
geometrical alterations and subsequently the alterations in RV longitudinal 
motion. However, according to previous studies the location of the pericardial 
opening is also crucial in whether it results in reduction of longitudinal RV 
function or not (89). In study III, global RV performance assessed by RIMP 
(prolonged), RVFAC, and RV-LS, were equally impaired following both AVR 
and MIAVR. The only RV echocardiographic parameter that diverged between 
AVR and MIAVR was RV-LSR. LSR has shown to be the best measure of 
intrinsic myocardial contractility (90, 91). Our findings demonstrate that 
myocardial contractility was preserved following MIAVR but not following 
AVR, despite longer cardiopulmonary bypass time in the MIAVR arm. In 
addition, the stroke volume was preserved following MIAVR but decreased 
following AVR, further strengthening our findings.  
In contrast to study II, RIMP was deteriorated (prolonged) in study III. The 
difference in the state of myocardial ischemia between these two studies 
might provide an explanation for the diversion in RIMP alterations. In study 
II, the majority of patients had 3-vessel disease and significant ischemia was 
revealed on DSE, while in study III patients with significant ischemia and 
requiring CABG were excluded from the study. Thus, RIMP might rather 
measure the burden of ischemia on myocardial function.  
In study I, using MPI assessed by PW-DTI of four different sites around the 
basal portion of the LV, an improvement in global LV performance was 
observed post-CABG at both rest and peak DSE. In contrast to MPI, 
traditional measures of LV function such as WMSI and LVEF did not improve 
at rest following CABG as compared to baseline. Consistent with previous 
studies, LVEF did not improve at rest following CABG as compared to pre-
CABG (92-94). The effect of CABG on LVEF has been divergent in previous 
studies. While some studies have reported an improvement in resting LVEF 
following CABG, others have reported no improvement in resting LVEF, but 
improvement in LVEF only during stress (93, 94). Several factors have been 
recognized as important determinants of improvement in LVEF after CABG. 
Substantial myocardial viability has been regarded as a crucial factor to 
obtaining functional improvement after CABG. However, in some studies that 
only included patients with substantial amount of viable myocardium, 
resting LVEF did not improve in 48% of the cohort following CABG. On the 
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other hand, in these patients peak stress LVEF improved following CABG 
(92). Additional factors influencing recovery in LVEF include: i) presence of 
extensive scar tissue which might prevent an increase in LVEF despite viable 
myocardium(95); and ii) graft occlusion after CABG which may hamper 
cardiac functional recovery of viable myocardium following CABG (96). 
Improvement in LV function at rest has previously been considered an 
indicator for the success of CABG in patients with advanced CAD (94). 
Considering the above mentioned limitations of LVEF to quantify 
improvement in LV functional recovery following CABG, MPI may have an 
incremental value in the assessment of LV function after CABG. 
In study IV, we demonstrate that postoperative BNP with a cut-off value of 
602-761 pg/ml, at 3-months after CABG and in a stable clinical setting, is a 
strong predictor of MACEs 5 years after CABG. Patients who had MACEs at 
5-years follow-up had significantly higher levels of BNP compared to patients 
without events. These results indicate that BNP is a powerful prognostic 
marker of long-term events following CABG. Our results are partly in accord 
with the results of previous studies evaluating the role of BNP as a prognostic 
marker for cardiovascular events in patients after cardiac surgery. Nozohoor 
et al (97) showed that BNP obtained the first day after CABG predicts one-
year mortality. However, in a study by Fellahi et al (98), BNP was analyzed 
only days after cardiac surgery in a mixed cohort of patients undergoing 
CABG and aortic valve replacement surgery while patients were still staying 
in the ICU. The results of this study revealed that early post-surgery BNP is 
only predictive of events in patients with aortic valve replacement and not in 
patients with CABG. In another study by Fox et al (99), only pre-operative 
BNP was an independent predictor of heart failure hospitalization after 
CABG, while peak early post-operative BNP was not. To our knowledge, the 
present study is the first one to evaluate the prognostic significance of BNP 
obtained a few months after CABG and in patients with clinically stable 
conditions.  
In the subpopulation of patients with DTI, a strong correlation between BNP, 
LVMPI, RIMP and LVEF, respectively, was observed. However, no significant 
correlation was observed following CABG. We speculate that the state of 
ischemia prior to CABG might influence RIMP, LVMPI, BNP, and LVEF in the 
same direction. However, these markers react differently to the relief from the 
burden of ischemia following revascularization surgery. Cardiac time 
intervals are sensitive markers of ischemia, while BNP reflects the state of 
mechanical adaption of the heart. Previous studies show that 
echocardiographic recovery of cardiac function may take up to one year (100). 
In study I, no improvement was observed in resting LVEF, while a significant 
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improvement in LVEF at peak stress was observed. In our study, BNP was 
analyzed 3 months after CABG, which may be too short for reflecting the 
adaptive mechanical changes following CABG. 
As our knowledge is growing and novel echocardiographic modalities are 
emerging, our understanding of myocardial function and its physiological 
response/adaptation to pericardial opening and its functional recovery from 
burden of ischemia and valvular heart disease is improving. 
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5.1 LIMITATIONS 
The main limitation of study I, and II was lack of a gold standard method 
reference method for assessment of LV- and RV function such as EF by 
cardiac magnetic resonance, or EF by 3D echocardiography. We lack a 
healthy control group to characterize the alterations in RIMP and LV MPI at 
rest and peak DSE in this group compared to the patients with CAD. 
However, as patients were examined four times during the course of study, 
they serve as their own controls. The study cohort was small. However, 
power calculations had revealed that the size of the cohort would be enough 
to detect the changes in the examined parameters. Similarly, one of 
limitations of study III was small sample size. And another was using 
different cardioplegia strategies between the AVR- and MIAVR group. The 
pericardium was closed following MIAVR but not following AVR could be 
mentioned as another limitation since it may influence the result of metrics 
assessing longitudinal RV function and the follow-up was too short. In 
study IV, BNP was assessed prior to CABG and at 3 months follow-up. It 
would have been interesting to assess BNP, also long time after CABG in 
order follow changes in BNP value over time. Echocardiographic 
measurements were also assessed 3 months after CABG which may be too 
short for some parameters to detect changes at rest.  
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6 CONCLUSIONS 
Echocardiographic assessment of cardiac function can in some scenarios 
be challenging despite advances in the current techniques of 
echocardiography imaging. While some modalities are perfectly suitable in 
certain clinical scenarios, they may not be suitable in other situations, due 
to certain limitations in each modality. Thus, it is important to employ 
several modalities for assessment of cardiac function. Our studies provide 
insights into assessment of cardiac function following CABG and surgical 
aortic valve replacement. While EF is widely used, it has important 
limitations with moderate accuracy. Further, improvement in LV function 
following CABG has been used as an echocardiographic marker of 
successful CABG. Although in study I, as in conjunction with previous 
studies, EF did not improve despite an improvement in clinical parameters. 
On the other hand, an improvement in LVMPI was observed. Thus, LVMPI, 
an expression of different cardiac time intervals may have incremental 
value in the assessment of cardiac function following CABG. 
In Study II; TAPSE and RVS declined following CABG. On the contrary, and 
consistent with clinical parameters RIMP improved both at rest and at peak 
DSE following CABG. While TAPSE and RVS represent global RV function 
under normal conditions, they may not represent global RV function 
following CABG due to altered cardiac geometry and cardiac motion. Our 
findings suggest that, RIMP might constitute additional information  in the 
evaluation of RV function following CABG. 
In Study III, RV function is a reflection of preload, afterload and 
contractility. While contractility is the intrinsic myocardial property, preload 
and afterload are determined by a variety of hemodynamic factors. RV 
function is sensitive to changes in loading conditions. Further, many of 
metrics in assessment of RV function are load dependent. In our study, 
TAPSE and RVS, in conjunction with other load dependent measures of RV 
function, deteriorated following both AVR and MIAVR. While, less load 
dependent LSR representing myocardial contractility, remained unchanged 
following MIAVR but deteriorated following AVR. Our results suggest that 
an accurate assessment of RV function should both load dependent and 
load independent metrics.  
In study IV, postoperative BNP assessed in a stable clinical setting following 
CABG, provided a good marker for future MACEs, 5 years after CABG. BNP 
might provide valuable prognostic information in patients undergoing 
cardiac surgery and can potentially be incorporated as a diagnostic marker 
at the regular clinical follow-up of the patients following CABG. 
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7 FUTURE PERSPECTIVE 
Introducing Two-dimensional echocardiography allowed visualization of 
cardiac structure and function in real time, opened new possibilities in 
physical examination and revolutionized the patient management. The 
potential and utility of ultrasound is unlimited and the development has been 
rapid and multi directional. While the image quality has consistently 
improved and new modalities are emerging, smaller and smaller ultrasound 
devices are designed. Currently, ultrasound devices are small enough to fit 
in the pocket and known as “pocket ultrasounds”, are commercially 
available. Pocket ultrasounds are gaining popularity among cardiologists. 
Will future cardiologists carry a stethoscope in one pocket and a “pocket 
ultrasound” in the other one? Or the development will go so far that the 
future cardiologist will carry a “pocket ultrasound” along with the 
stethoscope? More than 200 years ago, the stethoscope, a tube filled with air, 
which enables conducting sound, replaced direct placement of the ear on the 
chest. Certainly, the stethoscope revolutionized the diagnostic of cardiac 
disease at that time. However, in the era of digitalization and an urge for 
diagnostic accuracy, maybe the role of the stethoscope is going to become 
limited and the ultrasound will gain new grounds. Furthermore, the future 
development and implementation of novel pocket Doppler echocardiographic 
modalities and indexes such as strain, harmonic power, perfusion 
echocardiography and others, will have a great impact, permitting the rapid 
advanced assessment and management of patients with cardiovascular 
diseases  
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